Monday, June 29, 2015

Best Consumer Service Stocks To Buy For 2016

Best Consumer Service Stocks To Buy For 2016: Nobility Homes Inc. (NOBH)

Nobility Homes, Inc., through its subsidiaries, designs, manufactures, and sells a line of manufactured homes in Florida. It offers homes under the trade names of Kingswood, Springwood, Springwood Special, Tropic Isle Special, Regency Manor Special, and Special Edition. The company sells its manufactured homes through a network of its own retail sales centers; and to independent manufactured home retail dealers and manufactured home communities on a wholesale basis. It also provides retail insurance services, which involves placing various types of insurance, including property and casualty, automobile, and extended home warranty coverage, with insurance underwriters on behalf of its customers in connection with their purchase and financing of manufactured homes. As of October 31, 2009, the company operated 15 retail sales centers in north and central Florida. Nobility Homes, Inc. was founded in 1967 and is headquartered in Ocala, Florida.

Advisors' Opinion:
  • [By Vanina Egea]

    Nobility Homes Inc. (NOBH)

    Finally, Gabelli reported owning 234.950 shares of Nobility Homes, sized at 5.97% of the companys shares outstanding and 0.01% of Gabellis portfolio. The company has a market cap of $44.63 million, with a P/E of 59.6 and P/S of 2.41.

  • source from Top Penny Stocks For 2015:http://www.seekpennystocks.com/best-consumer-service-stocks-to-buy-for-2016.html

Tuesday, June 23, 2015

Hot Penny Companies To Buy For 2016

Hot Penny Companies To Buy For 2016: Key Tronic Corporation(KTCC)

Key Tronic Corporation, doing business as KeyTronicEMS Co., together with its subsidiaries, provides electronic manufacturing services (EMS) to original equipment manufacturers primarily in the United States, Mexico, and China. Its EMS services include product design, surface mount technologies for printed circuit board assembly, tool making, precision plastic molding, liquid injection molding, automated tape winding, prototype design, and full product builds. The company also manufactures keyboards and other input devices for personal computers. Key Tronic markets its products and services primarily through its direct sales department aided by field sales people and distributors. The company was founded in 1968 and is headquartered in Spokane Valley, Washington.

Advisors' Opinion:
  • [By Lisa Levin]

    Computer Peripherals: This industry rose 2.21% by 10:15 am ET. The top performer in this industry was Key Tronic (NASDAQ: KTCC), which gained 0.3%. Key Tronic's trailing-twelve-month ROE is 14.57%.

  • source from Top Stocks To Buy For 2015:http://www.topstocksforum.com/hot-penny-companies-to-buy-for-2016.html

Thursday, June 18, 2015

10 Best Dow Dividend Stocks To Buy Right Now

Whole Foods (NYSE:WFM) is still most commonly identified as the supermarket for organic, natural, and healthier foods. While plenty of shoppers know about chains like Sprout's (NYSE:SFM), Natural Grocers (Nasdaq:NGVC), and The Fresh Market (NYSE:TFM), just about everybody has been to a Whole Foods once. With more organic/healthy food options in the stock market, not to mention a significant expansion at conventional retailers like Wal-Mart (NYSE:WMT) and Target (NYSE:TGT), just how special is Whole Foods anymore? While the numbers continue to support the notion that Whole Foods is an uncommonly well-run retailer with considerable growth potential, it's increasingly challenging to justify the price on the shares.

The Third Quarter Was Fine, But Not Thesis-Changing
Operationally, it doesn't look like Whole Foods is running dramatically ahead of expectations. Revenue rose 12% this quarter, actually coming in below the 13.4% average growth estimate. Same-store sales were good, though, as comparable store sales grew 7.5% (ahead of the 7% estimate) and identical store sales rose 7.2%. Within that number, transaction count increased about 4%, with 3% coming from price.

5 Best Low Price Stocks To Watch Right Now: BHP Billiton Limited(BHP)

BHP Billiton Limited, together with its subsidiaries, operates as a diversified natural resources company worldwide. The company engages in the exploration, development, and production of oil and gas; mining and refining of bauxite into alumina, and smelting of alumina into aluminum metal; and mining of copper, silver, lead, zinc, molybdenum, uranium, gold, diamonds, and titanium minerals, as well as development of potash deposits. It also involves in the mining and production of nickel products, manganese ore, and manganese metal and alloys, as well as in the mining of iron ore, metallurgical coal, and thermal coal. BHP Billiton Limited sells its copper, lead, and zinc concentrates, and alumina to smelters; copper cathodes to wire rod mills, brass mills, and casting plants; uranium oxide to electricity generating utilities; rough diamonds to diamond buyers and diamond manufacturers; nickel products to stainless steel, specialty alloy, foundry, chemicals, and refractory ma terial industries; metallurgical coal to steel producers; and energy coal to power stations, power generators, and industrial users. The company, formerly known as BHP Limited, was founded in 1885 and is headquartered in Melbourne, Australia.

Advisors' Opinion:
  • [By Varun Chandan, Arora]

    BHP Billiton's (NYSE: BHP  ) Nickel West unit in Australia has been on investors' radar ever since the mining giant announced that it may spin off or divest its non-core assets, which also include its manganese and aluminum mining businesses. It is expected that Andrew Mackenzie, who took over the reins of the company last year, plans to make a final call on these businesses by the year-end. For Nickel West, BHP Billiton couldn't have asked for a better time. According to Citigroup's latest survey, the nickel market is set to fall into a big deficit next year.

  • [By Namitha Jagadeesh]

    BHP Billiton Ltd. (BHP) and Rio Tinto Group, the world�� largest mining companies, advanced at least 3.5 percent. Repsol SA increased the most in a month after saying it discovered natural gas in Algeria. Lagardere SCA (MMB) lost the most in four months after selling its stake in European, Aeronautic, Defence & Space Co.

10 Best Dow Dividend Stocks To Buy Right Now: GTSI Corp.(GTSI)

GTSI Corp., together with its subsidiaries, provides information technology (IT) hardware and solutions to federal, state, and local government customers, as well as to prime contractors in the United States. It offers IT infrastructure solutions, including data center consolidation and optimization solutions, server and desktop virtualization solutions, cloud computing solutions, network modernization solutions, unified communications and collaboration solutions, database and software development solutions, asset management solutions, and financial services solutions. The company also provides various services comprising software development and maintenance, program and project management, database development and maintenance, and legacy systems modernization services. In addition, it offers computer hardware, software, and peripheral products, as well as provides technical support and assistance services. The company markets and sells its computer hardware and software, and solutions through GTSI.com. It has strategic partner relationships with Cisco, Hewlett Packard, Crossmatch Technologies, Microsoft, Dell, Oracle, Net App, and Hitachi. GTSI Corp. was founded in 1983 and is headquartered in Herndon, Virginia.

Advisors' Opinion:
  • [By Geoff Gannon]

    I picked GTSI (GTSI) for the Ben Graham: Net-Net Newsletter.

    And that is not a good business. It lost money in about half of the last 10 years. It had no history of earning more than about 6% on equity over time. It was a truly terrible business.

  • [By Geoff Gannon]

    Someone who reads my articles sent me this question: My��uestion has to do with the type of investments you tend to put your energy toward. Evaluating a net-net is a whole lot different than evaluating a company that has a competitive advantage and trades at much higher multiples. To me, the net-net evaluation process is a whole lot more straightforward, as there are fewer intangibles (if any) and less prediction about the future involved. I don't have to worry about whether GTSI (GTSI) has any competitive advantage ��I know it doesn't. Then again, I look at a company like Becton Dickenson (BDX) and I see a highly predictable company with a decent moat selling at a reasonable price. I can look at BDX and figure I might earn 10-15% annually over a long time frame. That's really different from thinking about investing in a net-net where I can see how it's 30-50% undervalued now, but it's not something I'm going to hold onto for decades. It's more of a matter of waiting for that one-time "pop" that will happen sometime in the next 1-5 years. How do you decide where to put your energy?

  • [By Geoff Gannon]

    I would never assume that $1 of retained earnings at GTSI (GTSI) was worth $1. It�� not.

    So it would be hard to buy GTSI on an earnings basis. I didn��. I bought it for the Ben Graham: Net-Net Newsletter�� model portfolio simply based on its cash, receivables, and stake in another company. Those 3 things meant the company�� liquidation value was higher than the price I paid for the stock.

10 Best Dow Dividend Stocks To Buy Right Now: AU Optronics Corp (AUO)

AU Optronics Corp. engages in the design, development, manufacture, assembly, and marketing of thin film transistor liquid crystal displays and other flat panel displays. The company operates in two segments, Display and Solar. It offers a range of display panels for use in mobile PCs, such as notebooks and tablets; desktop monitors; consumer electronics products consisting of mobile phones, digital still cameras, portable navigation displays, digital camcorders, automobile displays, amusement and printer displays, and portable gaming consoles; and LCD televisions. The company sells its panels to original equipment manufacturing service providers who manufacture products on a contract basis for brand companies; and to brand companies on a direct shipment basis. It also manufactures upstream and midstream products, such as polysilicons, ingots, wafers, and solar cells; designs, develops, and manufactures solar photovoltaic (PV) modules; produces solar PV systems; and provid es various value-added services for solar PV systems projects. AU Optronics Corp. operates in the People�s Republic of China, Taiwan, Singapore, Korea, and internationally. The company was formerly known as Acer Display Technology, Inc. and changed its name to AU Optronics Corp. in May 2001. AU Optronics Corp. was founded in 1996 and is based in Hsinchu, Taiwan.

Advisors' Opinion:
  • [By Seth Jayson]

    Basic guidelines
    In this series, I examine inventory using a simple rule of thumb: Inventory increases ought to roughly parallel revenue increases. If inventory bloats more quickly than sales grow, this might be a sign that expected sales haven't materialized. Is the current inventory situation at AU Optronics (NYSE: AUO  ) out of line? To figure that out, start by comparing the company's inventory growth to sales growth. How is AU Optronics doing by this quick checkup? At first glance, pretty well. Trailing-12-month revenue increased 6.5%, and inventory decreased 13.1%. Comparing the latest quarter to the prior-year quarter, the story looks decent. Revenue increased 14.9%, and inventory contracted 13.1%. Over the sequential quarterly period, the trend looks worrisome. Revenue dropped 7.7%, and inventory grew 7.7%.

  • [By Monica Gerson]

    AU Optronics (NYSE: AUO) shares reached a new 52-week low of $3.06. AU Optronics' PEG ratio is 2.34.

    CBL & Associates Properties (NYSE: CBL) shares fell 5.20% to reach a new 52-week low of $18.43 after the company reported Q3 results.

10 Best Dow Dividend Stocks To Buy Right Now: Samson Oil and Gas Ltd (SSN)

Samson Oil & Gas Limited (Samson), incorporated on April 6, 1979, is engaged in exploration and development of oil and natural gas properties in the United States. Samson owns a working interest in each of its three material producing properties, through which it has entered into operating agreements with third parties under which the oil and gas are produced and sold. The Company also has 100% working interest in one exploration property and 50% to 100% in a second property. As of June 30, 2012, the Company�� properties included North Stockyard Project; State GC Oil and Gas Field, New Mexico; Davis Bintliff (Sabretooth Prospect), Brazoria County, Texas; Hawk Springs Project, Goshen County, Wyoming, and Roosevelt Project, Roosevelt County, Montana. As of June 30, 2012, the Company along with its subsidiaries produced approximately 87,956 barrels of oil and 214,463 thousand cubic feet of gas.

North Stockyard Project -Williston Basin, North Dakota

Samson has 34.5% working interest in 3,303 acres adjacent to the North Stockyard Oil Field, which is located in the Williston Basin in North Dakota and is operated by Zavanna LLC. Together with the Company�� working interest owners, it has drilled seven wells in this field, six in the Bakken formation and one in the Mission Canyon formation. During July 2012, the Harstad #1-15H well averaged 15 barrels of oil per day (BOPD). The Leonard-23H (10% working interest, 37.5% after non-consent penalty) is a Mississippian Middle Bakken Formation. In July 2011, this well averaged 46 barrels of oil per day. The Company drilled its third Bakken well in the North Stockyard Field, the Gary-24H (37% working interest). During July 2012, this well averaged 75 BOPD. It drilled its fourth Bakken well in the North Stockyard Field, the Rodney-14H (27% working interest). In July 2011, this well averaged 92 BOPD. It drilled its fifth Bakken well in the North Stockyard Field in Williams County, North Dakota, the Earl 1-13H (32% working interest). In Jul! y 2011, the well averaged 193 BOPD. In June 2011, it drilled its sixth Mississippian Bakken well in the North Stockyard field in Williams County, North Dakota, the Everett 1-15H (26% working interest). As of June 30, 2012, the North Stockyard project had net proved reserves of 598,500 barrels of oil and 757,800 thousand cubic feet (of natural gas).

State GC Oil and Gas Field, New Mexico

The State GC oil and gas field is located in Lea County, New Mexico, and covers approximately 600 acres. As of June 30, 2012, the field had two wells, the State GC#1 and State GC#2. Average daily production during the year ended June 30, 2012 from the State GC oil and gas field was approximately 43 BOPD and 37 million standard cubic feet per day. As of June 30, 2012, the State GC oil and gas field had net proved reserves of 65,500 barrels of oil and 87,300 thousand cubic feet (of natural gas).

Davis Bintliff #1 Well (Sabretooth Prospect), Brazoria County, Texas

The Davis Bintliff #1 well is operated by Davis Holdings. During the year ended June 30, 2012, this well averaged 29 BOPD and 2.61million cubic feet per day. As of June 30, 2012, the Davis Bintliff well had net proved reserves of 700 barrels of oil and 66,400 Thousand cubic feet (of natural gas).

Hawk Springs Project, Goshen County, Wyoming

The Company has 37.5%-100% working interest in Hawk Springs Project. The Spirit of America 1 replacement well, Spirit of America 2, was successfully drilled to a total depth of 10,634 feet during the fiscal year ended June 30, 2012 (fiscal 2012).

Roosevelt Project, Roosevelt County, Montana

The well was drilled to a total measured depth of 14,972 feet with the horizontal lateral remaining within the target zone for the entire lateral length. approximately 3,425 barrels of oil have been produced.

Advisors' Opinion:
  • [By James E. Brumley]

    Had Samson Oil & Gas Limited (NYSEMKT:SSN) made the late-July surge and subsequent early-August pullback and then gotten stuck in the mud again, I might not even bother taking a look at it. That's not how it happened though. Since the pullback, SSN has perked up again, perhaps not as hot as it was with the initial rally at the end of last month, but more than hot enough to get my attention. I suspect another surge - perhaps a longer-lasting surge - is in the cards.

10 Best Dow Dividend Stocks To Buy Right Now: State Street Corporation(STT)

State Street Corporation, a financial holding company, provides various financial products and services to institutional investors worldwide. The company?s Investment Servicing business line provides products and services, including custody, product- and participant-level accounting; daily pricing and administration; master trust and master custody; record-keeping; foreign exchange, brokerage, and other trading services; securities finance; deposit and short-term investment facilities; loan and lease financing; investment manager and alternative investment manager operations outsourcing; and performance, risk, and compliance analytics. This segment also offers shareholder services, which comprise mutual fund and collective investment fund shareholder accounting. Its Investment Management business line provides a range of investment management, investment research, and other related services, such as securities finance; and strategies for managing passive and active financ ial assets, such as enhanced indexing and hedge fund strategies for U.S. and global equities and fixed-income securities. The company serves mutual funds, collective investment funds and other investment pools, corporate and public retirement plans, insurance companies, foundations, endowments, and investment managers. State Street Corporation was founded in 1832 and is headquartered in Boston, Massachusetts.

Advisors' Opinion:
  • [By Adam Levine-Weinberg]

    One way to grow your retirement savings is by investing in low-fee index funds, such as State Street's (NYSE: STT  ) ETF that tracks the S&P 500 index: SPDR S&P 500 (NYSEMKT: SPY  ) . State Street invented the ETF concept two decades ago and remains a leader in the ETF market, with index funds tracking individual S&P 500 sectors as well as the full index. (State Street has actively managed funds, as well.)

  • [By Holly LaFon]

    In the fourth quarter, Yacktman�� biggest additions to his holdings were Research In Motion (RIMM) and Avon Products (AVP). He also surprised followers by venturing into financials, with new positions in Goldman Sachs (GS), Bank of America (BAC), State Street Corp. (STT) and Northern Trust Corp. (NTRS).

  • [By Sean Williams]

    Similarly, investment management and services company State Street (NYSE: STT  ) added 4.1% in spite of a lack of news. The move does, however, come just a few days after TheStreet.com reiterated its buy recommendation on the stock. It's also worth noting that State Street Chairman and CEO Joseph Hooley will be presenting at the Morgan Stanley�Financials Conference in two weeks. Usually conferences like these allow investment firms like State Street to instill confidence in analysts, and it's not uncommon to see upgrades (and downgrades) follow these meetings.

10 Best Dow Dividend Stocks To Buy Right Now: Rollins Inc. (ROL)

Rollins, Inc., through its subsidiaries, provides pest and termite control services to residential and commercial customers in North America. It offers pest control services, and protection against termite damage, rodents, and insects to homes and businesses, including hotels, food service establishments, food manufacturers, retailers, and transportation companies. The company also provides pest management and sanitation services and products to the food and commodity industries. It operates under the brand names of Orkin and PCO Services brand names, as well as under the Acurid service mark. The company also offers its services in Central America, the Caribbean, the Middle East, Asia, the Mediterranean, and Europe. As of December 31, 2010, it had 56 domestic franchises and 16 international franchises. The company, formerly known as Rollins Broadcasting, Inc., was founded in 1948 and is headquartered in Atlanta, Georgia.

Advisors' Opinion:
  • [By Rich Duprey]

    Pest control service provider�Rollins (NYSE: ROL  ) announced yesterday its third-quarter dividend of $0.09 per share, the same rate it's paid for the past two quarters after raising the payout 12.5% from $0.08 per share.

10 Best Dow Dividend Stocks To Buy Right Now: Redhill Biopharma Ltd (RDHL)

Redhill Biopharma Ltd. is an Israel-based biopharmaceutical company. The Company is focused on the development and acquisition of therapeutic candidates. The Company�� pipeline consists of six late clinical development therapeutic candidates, two of which have completed bioequivalence clinical trials subject to review and approval by the United States Food and Drug Administration and, in some cases, regulatory authorities in other countries. The Company�� six clinical stage therapeutic candidates include RHB-101, RHB-102, RHB-103, RHB-104, RHB-105 and RHB-106.

RHB-101

RHB-101 is a treatment of hypertension, heart failure and left ventricular dysfunction (following myocardial infraction) by means of controlled release of an active ingredient known as carvedilol, which is designed to be administered to patients on a once-daily basis. RHB-101 is based on a patented technology for the controlled release of drugs administered orally.

RHB-102

RHB-102 is a once-daily controlled release oral formulation of ondansetron. RHB-102 utilizes a technology called CDT that uses salts to provide a controlled release of ondansetron.

RHB-103

RHB-103 is an oral thin film formulation of rizatriptan intended for the treatment of acute migraine headaches. Migraine is a neurovascular disorder (related to nerves and blood vessels) characterized by recurrent headaches in one side or both sides of the head.

The product is based on a technology called VersaFilm.

RHB-104

RHB-104 is an antibiotic combination therapy for the treatment of Crohn's disease (with a PIII clinical study underway), as well as Multiple Sclerosis (with an ongoing PIIa clinical study) and Rheumatoid Arthritis. RHB-104 is a combination of clarithromycin, clofazimine and rifabutin, three generic antibiotic ingredients, in a single capsule.

RHB-105

RHB-105, an antibiotics and proton pump inhibitor drug targeting Helico! bacter Pylori infection. RHB-105 is a combination of three approved drug products omeprazole, which is a proton pump inhibitor (the natural body pump that produces the gastric acids used for digesting the food in the stomach), and amoxicillin and rifabutin which are antibiotics. Chronic infection with Helicobacter pylori irritates the mucosal lining of the stomach and small intestine.

RHB-106

RHB-106, is a tablet for the preparation and cleansing of the gastrointestinal tract prior to the performance of abdominal procedures. Its abdominal procedures include diagnostic tests, such as colonoscopy, barium enema or virtual colonoscopy, as well as surgical interventions, such as laparotomy.

The company competes with GlaxoSmithKline, Sanofi-Aventis Groupe, Hoffman-La Roche Ltd, Merck and Co., Inc, Ferring Pharmaceuticals and Salix Pharmaceuticals Inc.

Advisors' Opinion:
  • [By Monica Gerson]

    Breaking news

    Vitran Corporation (NASDAQ: VTNC) announced today that it has entered into a definitive arrangement agreement with TransForce pursuant to which TransForce has agreed to acquire all of the outstanding common shares of Vitran not already owned by TransForce for US$6.50 in cash per share, in accordance with TransForce's prior proposal. To read the full news, click here. ReneSola (NYSE: SOL) today announced it signed a Memorandum of Intent (MOI) to sell three utility-scale projects in Western China, with a total capacity of 60MW, to Jiangsu Akcome Solar Science & Technology Co on December 30, 2013. To read the full news, click here. Cooper Tire & Rubber Company (NYSE: CTB) today announced it has terminated the merger agreement with Apollo Tyres (NSE:ApolloTYRE). To read the full news, click here. RedHill Biopharma (NASDAQ: RDHL) today announced that it has entered into a definitive agreement with leading healthcare investor OrbiMed Israel Partners Limited Partnership, an affiliate of OrbiMed Advisors LLC, for the sale of RedHill's American Depository Shares and warrants in a private placement transactionor a total sum of $6.0 million. To read the full news, click here.

    Posted-In: Guggenheim US Stock FuturesNews Eurozone Futures Global Pre-Market Outlook Markets

Wednesday, June 17, 2015

Top 5 Promising Stocks To Buy For 2015

CSX (NYSE: CSX  ) has undergone a huge transformation over the past decade, as the steep spike in energy prices sent railroads from being nearly obsolescent modes of transportation to being a key mover of goods during the commodity boom. Even after that boom paused during the 2008 financial crisis, CSX stock rebounded sharply from its declines and has recently approached all-time-record highs.

But CSX faces a major challenge: how to handle a struggling coal market. With its geographic proximity to major coal production areas like the Appalachian region, CSX has sought ways to make the most of a tough situation in coal while also branching out into other promising markets. Let's take a closer look at CSX to see why its stock has continued to pick up steam lately.

CSX is firing on all cylinders
The quarterly results that CSX reported back in April are indicative of the company's overall success lately. The company broke its own records for net income and earnings per share, with gains of more than 2% in earnings coming in well above expectations. Although revenue remained flat, CSX was able to boost its dividend by 7% and initiate a $1 billion buyback to take place over the next two years.

Top Casino Stocks To Invest In 2016: GOFF, CORP. (GOFF)

Goff Corporation, incorporated on July 12, 2010, is a development-stage company. The Company, through its wholly owned subsidiary, Golden Glory Resources S.A., is engaged in mineral exploration. The Company's primary project is the La Frontera Gold Project located in the Aguadas Department, in Caldas, Colombia. The Project is being pursued as a potential bulk-tonnage, gold-silver target. Golden Glory acquired its leases on the La Frontera through a transaction with a Colombian company and holds a 100% working interest in the property. The Company through its subsidiary Golden Glory Resources, focuses on the La Frontera Gold Project covers prospective ground and merits continued gold exploration, including exploration diamond drilling. In April 2013, the Company has established a new, wholly owned subsidiary Golden Glory Resources Colombia SAS.

The La Frontera Project is in the Aguadas, Department Of Caldera, which is located approximately 60 kilometers south of Medellin, Colombia. A NI43-101 report is completed on the La Frontera Property, which identifies the potential for gold in both veins and a porphyry structure on the leases. The LGC-15011 Project (La Frontera Project) is located in the northern department of Caldas, Colombia (LGC-15011 has 30% in Antioquia), in the village of Puente Piedra, in the municipality of Aguadas.

Advisors' Opinion:
  • [By Brian Richards]

    Goff (NASDAQOTCBB: GOFF  ) , a social recruiting-company-turned-Colombian-gold miner, did not exist as an incorporated business before the summer of 2010 and did not trade as a public company until March 2013. Yet since its debut on the over-the-counter market, on average it has traded more shares each day than Apple or ExxonMobil.

Top 5 Promising Stocks To Buy For 2015: Legal & General Group PLC (LGEN)

Legal & General Group Plc is a provider of risk, savings and investment management products in the United Kingdom. The Company's operating segments include Protection and Annuities segment consisting of individual and group protection, individual and bulk purchase annuities, longevity and general insurance; Savings segment consisting of non-profit investment bonds, non-profit pensions (including self-invested personal pensions (SIPPs)), individual savings account (ISAs), retail unit trusts and retail platform businesses; Investment management segment consisting of institutional fund management and LGIM America (LGIMA); US Protection segment consisting of individual protection and universal life contracts, and Group capital and financing consists of shareholders��equity supporting the non profit Protection and Annuities and Savings businesses. In August 2013, Legal & General Group Plc announced the acquisition of Lucida Limited. Advisors' Opinion:
  • [By Rupert Hargreaves]

    Unfortunately, Prudential only offers a dividend yield of 2.4% at present, below that of its peers, such as Aviva (AV) and Legal & General (LGEN). Moreover, city analysts only expect Prudential to increase its payout by 10% this year and 5% during 2014.

Top 5 Promising Stocks To Buy For 2015: OvaScience Inc (OVAS)

OvaScience, Inc., incorporated on April 5, 2011, is a life science company developing products to improve the treatment of female infertility based on recent scientific discoveries about the existence of egg precursor cells. The Company holds license from Massachusetts General Hospital (MGH) to an issued patent and various patent applications directed to methods of identifying and purifying egg precursor cells, compositions comprising egg precursor cells and methods of using egg precursor cells to treat infertility and related disorders. The Company�� product candidates are AUGMENT and OvaTure. The Company�� designs AUGMENT to treat infertility due to poor egg quality.

The Company�� first product candidate is AUGMENT, stands for autologous germline mitochondria energy transfer. It designs AUGMENT to increase the success of in vitro fertilization (IVF) by isolating fresh mitochondria from a woman's own egg precursor cells and then adding the mitochondria into the woman's egg during IVF. Its second product candidate is OvaTure. OvaTure involves the creation of mature fertilizable eggs from a woman's own egg precursor cells. If successful, this would allow women with compromised eggs due to age or other factors to undergo IVF using their own higher quality eggs.

The Company competes with Novocellus Ltd., Auxogyn, Inc, and Ovacyte LLC.

Advisors' Opinion:
  • [By John Udovich]

    On Thursday, small cap infertility stock OvaScience Inc (NASDAQ: OVAS) surged 23.63% plus shares are up 372.9% since the start of the year���meaning its worth taking a closer look at the stock along with the performance of female or reproductive health stocks the Female Health Co (NASDAQ: FHCO) and�Utah Medical Products, Inc (NASDAQ: UTMD)�along with the Vanguard Health Care ETF (NYSEARCA: VHT).

Top 5 Promising Stocks To Buy For 2015: IZEA Inc (IZEA)

IZEA, Inc. (IZEA), formerly IZEA Holdings, Inc., incorporated in February 2006, is a marketplace for consumer generated advertising, connecting advertisers with social media publishers, such as bloggers, tweeters and others in order to develop and distribute content throughout the blogosphere and social networks. The Company is a social media sponsorship, operating multiple marketplaces, which include WeReward, SponsoredTweet, SocialSpark, PayPerPost and InPostLinks. It generates its revenue through the sale of social media sponsorships (SMS) to its customers. Each platform the Company operates is designed to facilitate SMS transactions. Each platform provides advertisers with access to a network of publishers, workflow management, content control, payment processing, performance tracking and legal compliance. It has more than 50,000 registered advertisers in 157 different countries. Its publishers publish sponsored content to blogs, Twitter, Facebook and Foursquare and reach other existing platforms, such as Tumblr, LinkedIn, Google and Bing through syndication of that content. On May 12, 2011, the Company acquired IZEA Innovations, Inc. In December 2012, the Company acquired Twitter marketing platform FeaturedUsers.

During the year ended December 31, 2011, the Company derived 80% its revenue from advertisers for the use of its network of social media publishers to fulfill an advertiser sponsor requests for a blog post, tweet, click, purchase, or action. During 2011, it derived the remaining 20% revenue from various service fees charged to advertisers and publishers. Service fees to advertisers include fees charged for management of advertising campaigns through its platforms and inactivity fees for dormant accounts. Service fees to publishers include upgrade account fees for obtaining greater visibility to advertisers in advertiser searches in its platforms and inactivity fees for dormant accounts.

SocialSpark

SocialSpark is the Company�� blog marketing platf! orm. Through SocialSpark it provides robust targeting and detailed analytics to advertisers. The site allows advertisers to develop lists of blogs based on various criteria, such as relevancy, traffic and demographic data. The platform also enables advertisers to create social media campaigns with the click of a button and to observe campaign results in real time. SocialSpark is also used by brands interested in engaging in conversations with their consumer bases. This platform is an automated, scalable version of other blogger outreach services conducted by public relations agencies, such as Porter Novelli, Edelman and Ketchum.

SponsoredTweets

SponsoredTweets is an online marketplace, which allows consumers to connect directly with advertisers to engage in sponsored conversations through Twitter. Marketers pay for Twitter advertising campaigns on either a cost per tweet (CPT) or cost per click (CPC) basis. SponsoredTweets allows advertisers to hand pick individual tweeters, including celebrities, to participate in Twitter advertising campaigns.

WeReward

WeReward is a social-mobile incentive platform, which allows brands to drive purchases, reward loyalty and understand their customers. WeReward promotes businesses, consumer products and mobile applications through its application, which can be downloaded on iPhone and Android devices. Consumers are able to earn WeReward points at more than 15 million businesses in the United States. WeReward points act as a cash rebate through PayPal to create value for users. This platform is similar to CheckPoints.

PayPerPost and InPostLinks

PayPerPost and InPostLinks are online marketplaces designed to facilitate search engine and allow advertisers to connect directly with bloggers to develop relevant blog post content and place text link advertising within blog posts. Both systems allow advertisers to compensate bloggers with cash in exchange for content and links back to Websites.

! IZEAMedia and Staree

IZEAMedia (in Pilot) allows advertisers to place display advertising next to sponsored blog content. Staree (in Development) is an online platform designed to help celebrities better monetize multimedia content through SMS.

The Company competes with Facebook, Glam Media, Federated Media, BlogHer, Ad.ly, Mom Central, Foursquare and Groupon.

Advisors' Opinion:
  • [By Peter Graham]

    Small cap tech, mobile or cloud computing stocks SofTech, Inc (OTCMKTS: SOFT), Firstin Wireless Technology Inc (OTCMKTS: FINW) and Izea Inc (OTCMKTS: IZEA) have been getting some extra attention lately in various investment newsletters or alerts. That�� because at least one of these stocks appears to be the subject of paid third party promotions while another is the focus of an apparent investor relations campaign. Keeping that in mind, are these three tech orientated stocks going to bring profits to investors and traders or bring out the luddite in them? Here is a closer look:

Sunday, June 14, 2015

Hot Gas Companies To Invest In 2016

According to a new report by Cedigaz, the France-based international natural gas association, cited in the Oil & Gas Journal, global marketed natural gas production and "apparent" consumption last year grew at a slower pace than the previous year.

The report, published in April, said that global natural gas consumption grew by just 2.2%, to 3,348.7 billion cubic meters, as a "turbulent economic climate, ongoing geopolitical tensions, and security issues in Arab countries" weighed on growth. That rate of growth was 0.6% lower than 2011's 2.8% growth and even lower than the 10-year average of 2.7% annual growth. �

The decline in gas consumption growth comes despite a massive surge in North American natural gas supplies, which kept prices depressed for much of the past few years, making the fuel more attractive to utility companies, chemical manufacturers, and other companies with energy-intensive operations.

Not surprisingly, consumption in the U.S. rose 4.4%, while consumption among Organization for Economic Cooperation and Development nations grew 2.1%, with Japan reported a whopping 11% increase. �

Hot Gas Companies To Invest In 2016: Targa Resources Partners LP (NGLS)

Targa Resources Partners LP is a limited partnership formed by Targa Resources, Corp (Targa). The Company is a provider of midstream natural gas and natural gas liquid (NGL) services in the United States and is engaged in the business of gathering, compressing, treating, processing and selling natural gas and storing, fractionating, treating, transporting, terminaling and selling NGLs, NGL products, refined petroleum products and crude oil. It operates in two divisions: Natural Gas Gathering and Processing, which include Field Gathering and Processing and Coastal Gathering and Processing, and Logistics and Marketing, which includes Logistics Assets and Marketing and Distribution. On March 15, 2011, it acquired a refined petroleum products and crude oil storage and terminaling facility in Channelview, Texas. On September 30, 2011 it acquired refined petroleum products and crude oil storage and terminaling facilities in two separate transactions. On December 31, 2012, the Company acquired Saddle Butte Pipeline, LLC.

Natural Gas Gathering and Processing Division

The Company�� natural gas gathering and processing division consists of gathering, compressing, dehydrating, treating, conditioning, processing, transporting and marketing natural gas. The gathering of natural gas consists of aggregating natural gas produced from various wells through small diameter gathering lines to processing plants. It sells its residue gas either directly to such end users or to marketers into intrastate or interstate pipelines. The Field Gathering and Processing segment gathers and processes natural gas from the Permian Basin in West Texas and Southeast New Mexico and the Fort Worth Basin, including the Barnett Shale, in North Texas. The natural gas it processes is supplied through its gathering systems which, in aggregate, consist of approximately 10,400 miles of natural gas pipelines. The segment�� processing plants include nine owned and operated facilities. During the year ended December 31! , 2011, the Company processed an average of approximately 612 million cubic feet/day (MMcf/d) of natural gas and produced an average of approximately 74 million barrels per day (MBbl/d) of NGLs.

The Field Gathering and Processing segment�� operations consist of the Permian Business, Versado, SAOU and the North Texas System. The Permian Business consists of the Sand Hills gathering and processing system and the West Seminole and Puckett gathering systems in West Texas. These systems consist of approximately 1,400 miles of natural gas gathering pipelines. Versado consists of the Saunders, Eunice and Monument gas processing plants and related gathering systems in Southeastern New Mexico. Versado consists of approximately 3,200 miles of natural gas gathering pipelines. Covering portions of 10 counties and approximately 4,000 square miles in West Texas, SAOU includes approximately 1,667 miles of pipelines in the Permian Basin that gather natural gas to the Mertzon, Sterling, and Conger processing plants. SAOU has 31 compressor stations to inject low pressure gas into the high-pressure pipelines.

The North Texas System includes two interconnected gathering systems with approximately 4,200 miles of pipelines, covering portions of 15 counties and approximately 5,700 square miles, gathering wellhead natural gas for the Chico and Shackelford natural gas processing facilities. The Chico gathering system consists of approximately 2,100 miles of primarily low-pressure gathering pipelines. Wellhead natural gas is either gathered for the Chico plant located in Wise County, Texas, and then compressed for processing, or it is compressed in the field at numerous compressor stations and then moved through one of several gathering pipelines to the Chico plant. Its Coastal Gathering and Processing segment assets are located in the onshore region of the Louisiana Gulf Coast and the Gulf of Mexico. LOU consists of approximately 875 miles of gathering system pipelines, covering approximately 3,800 ! square mi! les in Southwest Louisiana. The gathering system is connected to numerous producing wells and/or central delivery points in the area between Lafayette and Lake Charles, Louisiana. The processing facilities include the Gillis and Acadia processing plants, both of which are cryogenic plants.

Logistics and Marketing Division

The Company includes the activities necessary to convert mixed NGLs into NGL products and provide certain value added services, such as the fractionation, storage, terminaling, transportation, distribution and marketing of NGLs, as well as certain natural gas supply and marketing activities in support of its other businesses. Its Logistics Assets Segment uses its platform of integrated assets to receive, fractionate, store, treat, transport and deliver NGLs typically under fee-based arrangements. Its logistics assets are connected to and supplied in part by its Natural Gas Gathering and Processing assets and are primarily located at Mont Belvieu and Galena Park near Houston, Texas and in Lake Charles, Louisiana. Across the Logistics Assets segment, it owns or operates a total of 39 storage wells at its facilities with a net storage capacity of approximately 64 million barrels of oil (MMBbl), the usage of which may be limited by brine handling capacity, which is utilized to displace NGLs from storage. It operates its storage and terminaling facilities based on the needs and requirements of its customers. Its fractionation, storage and terminaling business is supported by approximately 940 miles of company owned pipelines to transport mixed NGLs and specification products.

The Company markets its own NGL production and also purchases component NGL products from other NGL producers and marketers for resale. During 2011, the Company�� distribution and marketing services business sold an average of approximately 273 MBbl/d of NGLs. Its wholesale propane marketing operations primarily sell propane and related logistics services to multi-state retailer! s, indepe! ndent retailers and other end-users. Its propane supply primarily originates from both its refinery/gas supply contracts and its other owned or managed logistics and marketing assets. In its refinery services business, the Company provide NGL balancing services through contractual arrangements with refiners to purchase and/or market propane and to supply butanes. It uses commercial transportation assets and contract for and use the storage, transportation and distribution assets included in its Logistics Assets segment to assist refinery customers in managing their NGL product demand and production schedules.

The Company�� NGL transportation and distribution infrastructure includes a range of assets supporting both third-party customers and the delivery requirements of its marketing and asset management business. It provides fee-based transportation services to refineries and petrochemical companies throughout the Gulf Coast area. As of December 31, 2011, its transportation assets include approximately 565 railcars that it lease and manage; approximately 74 owned and leased transport tractors and approximately 100 company owned tank trailers, and 18 company owned pressurized NGL barges.

The Company competes with Atlas Gas Pipeline Company, Copano Energy, L.L.C. (Copano), WTG Gas Processing, L.P. (WTG), DCP Midstream Partners LP (DCP), Devon Energy Corp (Devon), Enbridge Inc., GulfSouth Pipeline Company, LP, Hanlon Gas Processing, Ltd., J W Operating Company, Louisiana Intrastate Gas, Enterprise Products Partners L.P., DCP, ONEOK and BP p.l.c.

Advisors' Opinion:
  • [By abirk]

    Occidental Petroleum (OXY) is an oil-related stock. Occidental Petroleum Corporation (Occidental) conducts its operations through various subsidiaries and affiliates. The company operates in three segments: oil and gas; chemical; and midstream, marketing and other. The oil and gas segment explores for, develops and produces oil and condensate, natural gas liquids (NGLs) and natural gas. The chemical segment (OxyChem) mainly manufactures and markets basic chemicals and vinyls. The midstream, marketing and other segment (midstream and marketing) gathers, processes, transports, stores, purchases and markets oil, condensate, NGLs, natural gas, carbon dioxide (CO2) and power.

Hot Gas Companies To Invest In 2016: Baytex Energy Corp (BTE)

Baytex Energy Corp. (Baytex), incorporated on October 22, 2010, through its subsidiaries, are engaged in the business of acquiring, developing, exploiting and holding interests in petroleum and natural gas properties and related assets in Canada (in the provinces of British Columbia, Alberta and Saskatchewan) and in the United States (in the states of North Dakota and Wyoming). The Company acts as the financing vehicle for its subsidiaries by providing access to debt and equity capital markets. As of December 31, 2011, its primary assets are Baytex Energy Ltd. (Baytex Energy), which it owns. On February 3, 2011, the Company acquired heavy oil assets located in the Reno area of northern Alberta and the Lloydminster area of western Saskatchewan. On August 9, 2011, the Company acquired natural gas assets located in the Brewster area of west central Alberta. During the year ended December 31, 2011, it completed two dispositions of undeveloped lands; in the Kaybob South area of west central Alberta, it sold six sections of leasehold, including five sections with Duvernay rights, and in the Dodsland area in southwest Saskatchewan, it sold 32,600 net acres of leasehold in the halo of the field.

During 2011, the Company�� production averaged 50,132 barrel of oil equivalent per day, from its properties in Canada. During 2011, production averaged 50,132 barrel of oil equivalent per day. During 2011, light oil and natural gas liquid (NGL) production was 6,769 barrels per day. During 2011, heavy oil production was 35,252 barrels per day. During 2011, natural gas production was 48.7 million cubic feet per day. Its crude oil and natural gas operations are organized into three business units: Alberta/B.C., Saskatchewan and United States. Each business unit has a portfolio of mineral leases, operated and non-operated properties and development prospects. These plays include the Bakken/Three Forks in the Williston Basin of North Dakota and southeast Saskatchewan and the Viking in southwestern Saskatche! wan and eastern Alberta.

Saskatchewan Business Unit

As of December 31, 2011, the Saskatchewan Business Unit accounted for more than 38% of production. The Saskatchewan Business Unit's heavy oil operations include cold primary and thermal (steam-assisted gravity drainage) production. Production is generated from vertical, slant and horizontal wells using progressive cavity pumps capable of handling heavy oil combined with gas, water and sand. Once produced, the oil is delivered to markets in both Canada and the United States on pipelines, tanker trucks or railways. Heavy crude is blended with light-hydrocarbon diluents (such as condensate) prior to being introduced into a sales pipeline. The blended crude oil is then sold by Baytex. During 2011, production in the Saskatchewan Business Unit averaged approximately 20,958 barrels of oil equivalent per day, which was comprised of 19,828 barrels per day of heavy oil, 154 barrels per day of light oil and 5,860 thousand cubic feet per day of natural gas. During 2011, Baytex drilled 93 (87.9 net) wells in the Saskatchewan Business Unit resulting in 84 (78.9 net) oil wells, four stratigraphic test wells, four service wells, and one dry and abandoned well.

The Company�� Ardmore, Alberta is developed in the Sparky, McLaren and Colony formations. During 2011, average production was approximately 652 barrels per day of heavy oil and 158 thousand cubic feet per day of natural gas. During 2011, one well was drilled. As of December 31, 2011, Baytex had 34,000 net undeveloped acres in this area. Its Carruthers property consists of separate North and South oil pools in the Cummings formation. During 2011, 13 wells were drilled. During 2011, average production was approximately 2,444 barrels per day of heavy oil and 489 thousand cubic feet per day of natural gas. As of December 31, 2011, Baytex had 10,600 net undeveloped acres in this area. During 2011, the Company�� Celtic, Saskatchewan producing property produced averaged 3,013 ! barrels p! er day of heavy oil and 538 thousand cubic feet per day of natural gas. During 2011, Baytex drilled seven oil wells in the area. The Company�� Cold Lake, Alberta is a heavy oil property. Production is from the Colony, Upper McLaren, Rex and Sparky formations. During 2011, average oil production was approximately 270 barrels per day. During 2011, Baytex had 11,300 net undeveloped acres in this area.

During 2011, in Kerrobert SAGD project, the Company placed two new well pairs on production. During 2011, average production from the Kerrobert area was approximately 3,350 barrels per day of heavy oil, 154 barrels per day of light oil, and 1,999 thousand cubic feet per day of natural gas. During 2011, Baytex drilled five oil wells and eight service wells in this area. As of December 31, 2011, Baytex had 38,600 net undeveloped acres in this area. Lindbergh is a non-operated heavy oil property. Baytex has a 21.25% working interest in this property. During 2011, average production in this area was approximately 673 barrels per day of heavy oil and 71 thousand cubic feet per day of natural gas. During 2011, four wells were drilled in this area. As of December 31, 2011, Baytex had 800 net undeveloped acres in this area. During 2011, its Marsden/Epping/Macklin/Silverdale, Saskatchewan produced approximately 2,102 barrels per day of oil and 290 thousand cubic feet per day of natural gas. During 2011, nine oil wells were drilled in this area. Its Tangleflags is characterized by multiple-zone reservoirs with production from the Colony, McLaren, Waseca, Sparky, General Petroleum and Lloydminster formations. During 2011, Baytex drilled 11 horizontal oil wells in the Lloydminster formation. During 2011, average production was approximately 1,763 barrels per day of heavy oil and 543 thousand cubic feet per day of natural gas.

Alberta/B.C. Business Unit

The Alberta/B.C. Business Unit possesses a range of light oil, heavy oil and natural gas properties. During 2011, the Alberta/B.C.! Business! Unit produced light and heavy gravity crude oil, natural gas, and natural gas liquids from fields in Alberta and British Columbia and accounted for approximately 58% of production. During 2011, production from this business unit averaged 27,833 barrel of oil equivalent per day, which was comprised of 15,425 barrels per day of heavy oil, 5,282 barrels per day of light oil and NGL and 42.8 million cubic feet per day of natural gas. During 2011, the Alberta/B.C. Business Unit participated in the drilling of 71 wells resulting in 61 oil wells, one natural gas well, seven stratigraphic test wells, one service well and one dry and abandoned well. As of December 31, 2011, its net undeveloped lands in this business unit totaled approximately 474,000 acres. During 2011, production from Bon Accord area was averaged approximately 905 barrels per day of light oil and 1,742 million cubic feet per day of natural gas. Natural gas is processed at two Baytex-operated plants and oil is treated at three Baytex-operated batteries. During 2011, in this area, Baytex drilled 11 horizontal Viking oil wells. As of December 31, 2011, Baytex had 18,300 net undeveloped acres in this area.

The Company�� Darwin/Nina/Goodfish/Lafond, Alberta produces natural gas from the Bluesky formation. During 2011, production averaged approximately 3,746 million cubic feet per day of natural gas. As of December 31, 2011, Baytex had 27,300 net undeveloped acres in this area. During 2011, the Company�� Leahurst, Alberta produced averaged approximately 2,633 million cubic feet per day of natural gas and 13 barrels per day of NGL from this multi-zone, year-round access area. Natural gas production from the Edmonton, Belly River, Viking and Mannville formations is processed. Baytex holds a total of 263 net sections of oil sands leases in the Peace River oil sands area, which includes the legacy Seal area and the Reno area. During 2011, production from the Peace River area was 15,425 barrels per day, which was comprised of 13,746 barr! els per d! ay from Seal and 1,679 barrels per day from Reno. During 2011, Baytex drilled 25 cold horizontal production wells and seven stratigraphic test wells at Seal and two cold horizontal production wells at Reno. The Peace River area includes 152,500 net undeveloped acres, including 57,000 net undeveloped acres at Seal and 95,500 net undeveloped acres at Reno.

During 2011, the Company�� Pembina production averaged 2,633 barrels per day of light oil and NGL and 22,428 million cubic feet per day of natural gas. During 2011, Baytex participated in drilling 19 wells in this area, resulting in 17 oil wells, one natural gas well, and one dry and abandoned well. During 2011, Pembina area drilling included five operated and 12 non-operated Cardium horizontal wells and completed with multi-stage fracture stimulations. During 2011, the Company�� production from Red Earth area averaged approximately 42 million cubic feet per day of natural gas and 522 barrels per day of light oil and NGL. During 2011, the Company�� Richdale/Sedalia property�� production averaged approximately 3,845 million cubic feet per day of natural gas and eight barrels per day of NGL. During 2011, the Company�� production from Stoddart area averaged approximately 4,498 million cubic feet per day of natural gas and 713 barrels per day of oil and NGL. During 2011, production from Turin was averaged approximately 345 barrels per day of oil and NGL and 856 million cubic feet per day of natural gas. Production is from the Second White Specks, Milk River, Bow Island, Mannville, Sawtooth and Livingstone formations.

United States Business Unit

During 2011, the Company focused its activities on the light oil resource play located in the Divide and Williams Counties of North Dakota. Production is from horizontal wells using multi-stage hydraulic fracturing in the Bakken and Three Forks formations. As of December 31, 2011, Baytex owned approximately 61,000 (24,800 net) developed acres. During 2011, Baytex parti! cipated i! n the drilling of 34 Bakken/Three Forks oil wells. During 2011, net production from the United States properties averaged 1,341 barrels of oil equivalent per day.

Advisors' Opinion:
  • [By Ari Charney]

    Baytex Energy Corp (TSX: BTE, NYSE: BTE) is among the heavy crude-oriented E&Ps to which the firm recommends increased exposure.

    Although Baytex has risen 9.8 percent over the trailing 12-month period, the stock is down about 14 percent from its mid-June high. Nevertheless, analyst sentiment remains firmly bullish, at 18 ��uys,��three ��olds,��and one ��ell.��/p>

  • [By Robert Rapier]

    There are a number of quality Canadian E&P companies that are attractive at current prices. Among my favorites are Baytex Energy (NYSE: BTE, TSE: BTE), Cenovus Energy (NYSE: CVE, TSE: CVE) and Canadian Natural Resources (NYSE: CNQ, TSE: CNQ) I also like Peyto Exploration & Development (TSE: PEY, OTC: PEYUF) for aggressive investors. We have often discussed putting Peyto in one of the portfolios, but I would ideally like it a bit cheaper.

  • [By GURUFOCUS]

    Canadian Trusts- Baytex Energy Trust (BTE) | Yield: 6.1%
    - Enerplus Resources Fund (ERF) | Yield: 5.6%
    - Pengrowth Energy Trust (PGH) | Yield: 7.1%

  • [By Rich Duprey]

    Canadian oil and gas producer�Baytex Energy (NYSE: BTE  ) announced yesterday its monthly dividend payment for June of $0.22 Canadian per share, the same monthly rate it's paid since 2011.�The U.S. dollar equivalent is approximately $0.2162 per share, assuming a foreign exchange rate of $0.9826 USD-CAD.

Hot Recreation Companies To Invest In 2016: Petroleo Brasileiro Petrobras SA (PBR.A)

Petroleo Brasileiro SA Petrobras (Petrobras) is a Brazilian integrated oil and gas company. It operates in five segments: exploration and production; refining, commercialization and transport of oil and natural gas; petrochemicals; distribution of derivatives, electrical energy, biofuels and other renewable energy sources. Directly or through its subsidiaries, Petrobras is engaged in the research, extraction, refining, processing, commercialization and transport of oil from wells, shales and other rocks, its derivatives, natural gas and other liquid hydrocarbons, as well as in activities related to energy, promoting research, development, production, transport, distribution and commercialization of all forms of energy. As of December 31, 2010, it had 132 production platforms, 16 refineries, 291 vessels, 29,398 kilometers of pipelines, six biofuel plants, 16 thermoelectric plants, one pilot wind farm, 8,477 service stations and two fertilizer plants, as well as presence in 30 countries.

Exploration and Production

The domestic oil and gas exploration and production efforts are focused on the three basins offshore in Southeastern Brazil: Campos, Espirito Santo and Santos. The Campos Basin, which covers approximately 115,000 square kilometers (28.4 million acres) is the oil and gas basin in Brazil. At December 31, 2009, the Company was producing from 41 fields at an average rate of 1,693.6 mbbl/d of oil and held proved crude oil reserves representing 90% of the total proved crude oil reserves in Brazil. At December 31, 2009, the Company held proved natural gas reserves in the Campos Basin representing 53% of the total proved natural gas reserves in Brazil. It operated 38 floating production systems, 14 fixed platforms and 5,472 kilometers (3,400.3 miles) of pipeline and flexible pipes in water depths from 80 to 1,886 meters (262 to 6,188 feet). At December 31, 2009, the Company held exploration rights to 21 blocks in the Campos Basin, comprising 5884 square kilometers (1.4 millio! n acres)..

Petrobras have made discoveries of light oil and natural gas in the Espirito Santo Basin, which covers approximately 75000 square kilometers (18.5 million acres) offshore and 14,000 square kilometers (3.5 million acres) onshore. At December 31, 2009, the Company was producing from 46 fields at an average rate of 40.9 thousand barrels per day (mbbl/d) and held proved crude oil reserves, representing 1% of the total proved crude oil reserves in Brazil. On December 31, 2009, the Company held exploration rights to 23 blocks, six onshore and 17 offshore, comprising 8623 square kilometers (2.1 million acres).

The Santos Basin covers approximately 348,900 square kilometers (86 million acres) off the city of Santos, in the State of Sao Paulo. At December 31, 2009, the Company produced oil from two fields and one exploration area at an average rate of 14.4 mbbl/d and held proved crude oil reserves representing 1% of the total proved crude oil reserves in Brazil. It produces hydrocarbons and hold exploration acreage in eight other basins in Brazil.

Refining, Transportation and Marketing

As of December 31, 2009, the Company operated 92% of Brazil�� total refining capacity and supplied almost all of the refined product needs of third-party wholesalers, exporters and petrochemical companies. As of December 31, 2009, the Company owned and operated 11 refineries in Brazil, with a total net distillation capacity of 1,942 mbbl/d. It operates an infrastructure of pipelines and terminals and a shipping fleet to transport oil products and crude oil to domestic and export markets. The refineries are located near the crude oil pipelines, storage, facilities, refined product pipelines and petrochemical facilities, facilitating access to crude oil supplies and other users.The segment also includes petrochemical and fertilizer operations. As at December 31, 2009, the refining capacity in Brazil was 1,942 mbbl/d and the average throughput was 1,791 mbbl/d.

T! he Company owns and operates a network of crude oil and oil products pipelines in Brazil that connect the terminals, refineries and other primary distribution points. On December 31, 2009, the onshore and offshore, crude oil and oil products pipelines extended 13,996 kilometers (8,698 miles). It operates 27 marine storage terminals and 20 other tank farms with nominal aggregate storage capacity of 65 million barrels. The marine terminals handle an average 10,000 tankers annually.

The Company operates a fleet of owned and chartered vessels. It provides shuttle services between the producing basins offshore Brazil and the Brazilian mainland, domestic shipping and international shipping to other parts of South America, the Caribbean Sea and Gulf of Mexico, Europe, West Africa and the Middle East. The fleet includes double-hulled vessels and single-hulled vessels, which operate in South America and Africa only.

Distribution

The distribution segment sells oil products, which are produced by the supply operations. At December 31, 2009, the BR network included 7,221 service stations, or 19.2% of the stations in Brazil. The Company supplies and operates Petrobras Distribuidora S.A., which accounts for 38% of the total Brazilian distribution market. BR distributes oil products, ethanol and biodiesel, and vehicular natural gas to retail, commercial and industrial customers. In 2009, BR sold the equivalent of 767.4 mbbl/d of oil products and other fuels to wholesale and retail customers.

The Company also distributes oil products and biofuels under the BR brand to commercial and industrial customers. The customers include aviation, transportation and industrial companies, as well as utilities and government entities. It also sells oil products produced by the Supply operations to other retailers and to wholesalers.

Gas and Power

The natural gas business includes four activities: transportation (building and operating natural gas pipel! ine netwo! rks in Brazil), acquisition and regasification of LNG, equity participation in distribution companies, which sell natural gas to the users, and commercialization (purchase and resale). In January 2009, the Company completed construction of two LNG terminals, one in Rio de Janeiro with a send-out capacity of 20 mmm3 /d (706 mmcf/d).

International

The Company have operations in 24 countries outside Brazil, which encompasses all phases of the energy business. It is focusing the international upstream activities in the Gulf of Mexico and West Africa. During 2009, the Company conducted exploration and production activities in 21 countries outside Brazil (Angola, Argentina, Bolivia, Colombia, Ecuador, the United States, India, Iran, Libya, Mexico, Mozambique, Namibia, Nigeria, Pakistan, Peru, Portugal, Senegal, Tanzania, Turkey, Uruguay and Venezuela). At December 31, 2009, the total assets of the International Segment represented 7.4% of the Company�� total assets.

Advisors' Opinion:
  • [By Rudy Martin]

    In addition, we recommend buying shares in Brazilian energy giant Petroleo Brasileiro Petrobras S.A. (PBR.A).

    Despite a gradual rise in crude oil prices, problems with Brazil's economy, compounded by obstacles in Petrobras's scramble to finance significant on-shore and off-shore hydrocarbon discoveries, have ganged up to erode PBR.A's stock price this year.

Hot Gas Companies To Invest In 2016: Weatherford International Ltd(WFT)

Weatherford International Ltd. provides equipment and services used in the drilling, evaluation, completion, production, and intervention of oil and natural gas wells worldwide. It offers artificial lift systems, which include reciprocating rod lift systems, progressing cavity pumps, gas lift systems, hydraulic lift systems, plunger lift systems, hybrid lift systems, wellhead systems, and multiphase metering systems. The company also provides drilling services, including directional drilling, ?Secure Drilling? services, well testing, drilling-with-casing and drilling-with-liner systems, and surface logging systems; and well construction services, such as tubular running services, cementing products, liner systems, swellable products, solid tubular expandable technologies, and inflatable products and accessories. In addition, it designs and manufactures drilling jars, underreamers, rotating control devices, and other pressure-control equipment used in drilling oil and nat ural gas wells; and offers a selection of in-house or third-party manufactured equipment for the drilling, completion, and work over of oil and natural gas wells for operators and drilling contractors, as well as a line of completion tools and sand screens. Further, the company provides wireline and evaluation services; and re-entry, fishing, and thru-tubing services, as well as well abandonment and wellbore cleaning services; stimulation and chemicals, including fracturing and coiled tubing technologies, cement services, chemical systems, and drilling fluids; integrated drilling services; and pipeline and specialty services. It serves independent oil and natural gas producing companies. The company was founded in 1972 and is headquartered in Geneva, Switzerland.

Advisors' Opinion:
  • [By Canadian Value]

    - Weatherford International (WFT) which is a services company and a direct beneficiary of the boom in horizontal drilling and fracturing in the U.S.

  • [By Jake L'Ecuyer]

    Shares of Weatherford International (NYSE: WFT) got a boost, shooting up 10.02 percent to $20.25 after the company reported upbeat quarterly earnings. Weatherford reported its Q1 earnings of $0.13 per share on revenue of $3.60 billion.

  • [By Holly LaFon]

    Weatherford International Ltd. (0.4%) (WFT)(WFT - $17.36 - NYSE), based in Houston, Texas, finally resolved its tax accounting problems and various government investigations, which had been on-going for several years. It is now focused on growing its core businesses, enhancing profitability, reducing leverage and improving capital efficiency. The company is targeting total segment operating profit margin to reach 20% by 2016 from 11.3% in 2013 and reducing debt to capitalization from 52% to 25%. It aims to realize $500 million in annualized cost savings and sell four non-core businesses. Also, Weatherford plans to spin-off a portion of its international drilling rig business by the end of 2014 or early 2015. All available free cash flow generated and proceeds from asset sales will be used to reduce debt.From Mario Gabelli (Trades, Portfolio)'s Value 25 Fund first quarter 2014 shareholder commentary. Also check out: Mario Gabelli Undervalued Stocks Mario Gabelli Top Growth Companies Mario Gabelli High Yield stocks, and Stocks that Mario Gabelli keeps buying Currently 0.00/512345

    Rating: 0.0/5 (0 votes)

  • [By Johanna Bennett]

    Earlier this week, analysts at Credit Suisse reduced earnings estimates for Halliburton, Baker Hughes, Schlumberger (SLB) and Weatherford International (WFT).

Hot Gas Companies To Invest In 2016: Maverick Minerals Corp (MVRM)

Maverick Minerals Corporation (Maverick), incorporated on August 27, 1998, is an exploration-stage company. The Company is engaged in the acquisition, exploration, and development of prospective oils and gas properties and mineral properties. During the year ended December 31, 2011, the Company's business focus was to implement the terms of the Farmout Agreement pursuant to which were to earn an interest in certain oil and gas mineral leases located in Fort Bend and Wharton Counties, Texas.

The Company�� subsidiary includes Eskota Energy Corporation. On January 22, 2011, the Company completed drilling of its Initial Test Well on the Company's 4,513 acre Farm-Out property in Fort Bend County, Texas. As of December 31, 2011, the Company had not generated any revenues.

Advisors' Opinion:
  • [By Peter Graham]

    On Friday, small cap mining stocks Maverick Minerals Corp (OTCMKTS: MVRM) and Liberty Coal Energy Corp (OTCMKTS: LBTG) plus oil stock Gray Fox Petroleum Corp (OTCBB: GFOX) sank 30.9%, 16.67% and 11.2%, respectively. However, only one of these stocks appears to have been the subject of some kind of paid promotion in the form of an investment in some shares. So will these three small cap mining or oil stocks keep coming up empty for investors this week? Here is a closer look:

    Maverick Minerals Corp (OTCMKTS: MVRM) Has Been Quiet Lately

    Small cap Maverick Minerals Corp is an exploration stage company involved in the acquisition, exploration, and development of prospective oil and gas properties and mineral properties. On Friday, Maverick Minerals Corp sank 30.9% to $0.38 for a market cap of $6.13 million plus MVRM is up 280% over the past year and up 322.2% over the past five years according to Google Finance.

Saturday, June 13, 2015

5 Best Gold Stocks To Watch For 2016

The decision to lease solar panels to both the business and residential sectors has really paid off so far for SolarCity (NASDAQ: SCTY  ) . Market-conscious investors have had to notice the atmospheric rise of the company's stock over the past several months. With fresh, financial backing from Goldman Sachs (NYSE: GS  ) , the company is set to provide a wider customer base with its free installations, and fees below typical utility bills.�

Now that deals are being signed with municipalities, as well, SolarCity is sure to continue impressing Mr. Market. The disruptive leasing model has also caught the eye of competitor, SunPower (NASDAQ: SPWR  ) , but it is getting to the party a bit later than the Elon Musk-inspired SolarCity. Only time will tell if it's fashionably late or detrimentally late.

With a bit of a different model, First Solar offers a different approach to the solar market
Investors and bystanders alike have been shocked by First Solar's precipitous drop over the past two years. The stakes have never been higher for the company: Is it done for good, or ready for a rebound? If you're looking for continuing updates and guidance on the company whenever news breaks, The Motley Fool has created a brand-new report that details every must-know side of this stock. To get started, simply click here now.

5 Best Gold Stocks To Watch For 2016: CME Group Inc.(CME)

CME Group Inc. operates the CME, CBOT, NYMEX, and COMEX regulatory exchanges worldwide. The company provides a range of products available across various asset classes, including futures and options on interest rates, equity indexes, energy, agricultural commodities, metals, foreign exchange, weather, and real estate. It offers various products that provide a means of hedging, speculation, and asset allocation relating to the risks associated with interest rate sensitive instruments, equity ownership, changes in the value of foreign currency, credit risk, and changes in the prices of commodities. CME Group owns and operates clearing house, CME Clearing, which provides clearing and settlement services for exchange-traded contracts and counter derivatives transactions; and also engages in real estate operations. Its primary trade execution facilities consist of its CME Globex electronic trading platform and open outcry trading floors, as well as privately negotiated transact ions that are cleared and settled through its clearing house. In addition, the company offers market data services comprising live quotes, delayed quotes, market reports, and historical data services, as well as involves in index services business. CME Group?s customer base includes professional traders, financial institutions, institutional and individual investors, corporations, manufacturers, producers, and governments. It has strategic partnerships with BM&FBOVESPA S.A., Bursa Malaysia Derivatives, Singapore Exchange Limited, Green Exchange, Dubai Mercantile Exchange, Johannesburg Stock Exchange, and Bolsa Mexicana de Valores, S.A.B. de C.V., as well as joint venture agreement with Dow Jones & Company. The company was formerly known as Chicago Mercantile Exchange Holdings Inc. and changed its name to CME Group Inc. in July 2007. CME Group was founded in 1898 and is headquartered in Chicago, Illinois.

Advisors' Opinion:
  • [By Roberto Pedone]

    One financial market player that's starting to move within range of triggering a major breakout trade is CME Group (CME), which offers products across all major asset classes based on interest rates, equity indexes, foreign exchange, energy, agricultural commodities, metals, weather and real estate. This stock has been in play with the bulls so far in 2013, with shares up sharply by 48%.

    If you take a look at the chart for CME Group, you'll notice that this stock recently formed a triple bottom chart pattern at $70.42, to $69.88 and $70.28 a share. Following that bottom, shares of CME have now started to trend back above its 50-day moving average of $72.70 a share. That move is quickly pushing CME within range of triggering a major breakout trade.

    Traders should now look for long-biased trades in CME if it manages to break out above some near-term overhead resistance levels at $75.50 to $77.65 a share and then once it clears its 52-week high at $79.45 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action of 1.84 million shares. If that breakout hits soon, then CME will set up to enter new 52-week-high territory above $79.45, which is bullish technical price action. Some possible upside targets off that breakout are $90 to $100 a share.

    Traders can look to buy CME off any weakness to anticipate that breakout and simply use a stop that sits right below its 50-day at $72.70 a share or just below more support at $70 a share. One can also buy CME off strength once it takes out those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.

5 Best Gold Stocks To Watch For 2016: First Majestic Silver Corp.(AG)

First Majestic Silver Corp. engages in the production, development, exploration, and acquisition of mineral properties with a focus on silver in Mexico. The company owns interests in La Encantada Silver Mine comprising 4,076 hectares of mining rights and 1,343 hectares of surface land located in Coahuila; La Parrilla Silver Mine consisting of mining concessions covering an area of 69,867 hectares; and San Martin Silver Mine comprising approximately 7,841 hectares of mineral rights and approximately 1,300 hectares of surface land rights located in Jalisco. It also holds interests in Del Toro Silver Mine consisting of 393 contiguous hectares of mining claims and an additional 129 hectares of surface rights located in Zacatecas; Real de Catorce Silver Project comprising 22 mining concessions covering 6,327 hectares located in San Luis Potosi state; and Jalisco Group of Properties consisting of mining claims totalling 5,240 hectares located in Jalisco. The company was founded in 1979 and is headquartered in Vancouver, Canada.

Advisors' Opinion:
  • [By Monica Gerson]

    First Majestic Silver (NYSE: AG) is estimated to post its Q1 earnings at $0.10 per share on revenue of $63.35 million.

    Dr. Reddy's Laboratories (NYSE: RDY) is expected to report its Q4 earnings at $0.52 per share.

  • [By Doug Ehrman]

    It is no secret that precious metals companies have been taking a pounding for some time now. The SPDR Gold Trust (NYSEMKT: GLD  ) and iShares Silver Trust (NYSEMKT: SLV  ) , the gold and silver ETFs, have been hard hit and operating companies like First Majestic (NYSE: AG  ) and Barrick Gold (NYSE: ABX  ) have been hit even harder. Through all of these struggles, and in some cases because of them, one precious metals company continues to look attractive for the long term: Silver Wheaton (NYSE: SLW  ) .

  • [By Lisa Levin] Related AG Morning Market Losers First Majestic Silver (AG) in Focus: Stock Rises 5.9% - Tale of the Tape Related ARCI Top 4 Stocks In The Electronics Stores Industry With The Highest ROE Morning Market Movers

    The Dow jumped 0.77% to 17,074.40, while the NASDAQ composite index rose 0.47% to 4,436.25. The broader Standard & Poor's 500 index gained 0.53% to 1,978.08.

  • [By Dan Caplinger]

    On that theory, hard-hit energy stocks that have suffered from the crash in oil prices could stand to benefit. Continental Resources (NYSE: CLR  ) , for instance, lost more than half its value in the last four months of 2014 as the exploration and production company with a huge stake in the Bakken shale play in North Dakota suffered from worries about the sustainability of its long-term growth in light of falling oil. Similarly, many small-cap gold and silver miners struggled through a poor 2014, and so companies like First Majestic Silver (NYSE: AG  ) and IAMGOLD (NYSE: IAG  ) arguably have more to gain from a January bounce.

5 Best Biotech Stocks For 2016: Australian Dollar(AU)

AngloGold Ashanti Limited primarily engages in the exploration and production of gold. It also produces silver, uranium oxide, and sulfuric acid. The company conducts gold-mining operations in South Africa; continental Africa, including Ghana, Guinea, Mali, Namibia, and Tanzania; Australia; and the Americas, which include Argentina, Brazil, and the United States. It also has mining or exploration operations in the Democratic Republic of the Congo, Guinea, and Colombia. As of December 31, 2010, the company had proved and probable gold reserves of 71.2 million ounces. The company has a strategic alliance with Thani Dubai Mining Limited to explore, develop, and operate mines across the Middle East and parts of North Africa. AngloGold Ashanti Limited, formerly known as Vaal Reefs Exploration and Mining Company Limited, was founded in 1944 and is headquartered in Johannesburg, South Africa.

Advisors' Opinion:
  • [By Patricio Kehoe] stion arises: Why is First Eagle bullish regarding such a company? The answer might lie in the huge discount at which the third-largest gold producer by output is trading, along with a certain degree of long-term optimism.

    Huge Holdings Point to Long-Term Commitment

    Since First Eagle recently increased its stake in Anglogold by more than 20%, bringing his total holding to over 32.5 million shares, I believe we are looking at a long-term investment. I am keen on pointing this out, since the stock is currently performing very poorly, and has already lost around 275% of its value year to date. Above average production costs and plummeting gold prices have put a huge deal of pressure on the gold miner, leading to very poor results. In addition, since many of its operations are in geopolitically risky countries such as Mali and the Democratic Republic of Congo, shareholders have been shedding this stock in large volumes.

    Although Anglogold had a very rough year, and will continue to face elevated cash costs and reduced margins going into 2014, there are some positive signals looking forward. One of the most promising features, are the firm�� operations in South America and Australia, which are enjoying solid organic growth. Although investors will have to wait some years for assets in these regions to reach full production, large profits should be achieved in the long-term. In other words, First Eagle surely has its eyes set on the company�� new projects, and their future growth potential.

    Projected Growth and Low Price

    Another attractive feature investors must keep in mind is a stock�� growth potential. When looking at Anglogold, this becomes especially relevant, as a comparison to Barrick Gold Corp (ABX) will demonstrate. Anglogold currently offers 13.6% returns on invested capital, compared to Barrick�� -2.8%, and has an EBITDA growth rate of 465.7%, the highest in the industry. Thus, whereas the Canadian miner has a negative EPS

  • [By Rich Duprey]

    Considering the work stoppages and violent clashes that have become the norm at South African precious-metals mines, perhaps the miners were wondering exactly what they were getting for their money. An expose by South Africa's Daily Maverick has uncovered a system where miners such as AngloGold Ashanti (NYSE: AU  ) and BHP Billiton (NYSE: BHP  ) surreptitiously paid for the salaries of the heads of the local mining unions to keep the mine workers in line, and it's only because the miners sought to end the "uncomfortable arrangement" with the unions that the matter came to light.

5 Best Gold Stocks To Watch For 2016: NEW GOLD INC.(NGD)

New Gold Inc. engages in the acquisition, exploration, extraction, processing, and reclamation of mineral properties. The company primarily explore for gold, silver, and copper deposits. Its operating properties include the Mesquite gold mine in the United States; the Cerro San Pedro gold-silver mine in Mexico; and the Peak gold-copper mine in Australia. The company also has development projects, including the New Afton gold, silver, and copper project in Canada; and a 30% interest in the El Morro copper-gold project in Chile. The company was formerly known as DRC Resources Corporation and changed its name to New Gold Inc. in June 2005. New Gold Inc. was founded in 1980 and is headquartered in Vancouver, Canada.

Advisors' Opinion:
  • [By Ben Levisohn]

    On an adjusted basis, Eldorado Gold (EGO) has the longest reserve/resource life amongst our coverage companies (39 years) with Goldcorp (GG) having the longest reserve/resource life (23 years) amongst the senior producers versus the group average of 22 years. Kinross Gold (KGC) and Iamgold (IAG) have the shortest adjusted reserve/resource lives amongst the senior and mid-tier producers (18 and 14 years respectively). On a percentage basis, the companies most affected by the adjustment are New Gold (NGD) and Iamgold which both saw reserve/resource lives fall by 47% however, we note that despite the adjustment,�New Gold still has the second longest reserve/resource life in our group (37 years). Newmont Mining was the least affected by the adjustments with reserve/resource life declining by only 12% to 22 years from 25 years.

5 Best Gold Stocks To Watch For 2016: Renaissance Oil Corp (ROE)

Renaissance Oil Corp, formerly San Antonio Ventures Inc., is developing a diversified shale and mature fields portfolio for development in Mexico and Spain. The Company is partnered with Grupo SAMCA, a diverse industrial with operations in energy, mining, industrial minerals, agriculture, environmental and various other business lines in Spain. Advisors' Opinion:
  • [By ovenerio]

    In this article, let麓s see one of the most important financial ratios applying to stockholders, the best measure of performance for a firm's management: the Return on Equity (ROE), and we are going to analyze it in the case of Altria Group Inc. (MO), a $93.34 billion market cap company, which is the largest U.S. cigarette producer with roughly 50% share.

  • [By nnnguyen1221]

    Return on Equity (ROE):

    If you had to teach a child about investment Returns, one of the first investing songs they may learn perhaps may be entitled, ��OE-ROE-ROE your Float.��All kidding aside, ROE is one of Warren Buffett (Trades, Portfolio)�� measures of a healthy company.

  • [By Fast Weekly]

    One of my favorite metrics is return on equity (ROE). I want to be sure that the companies I own generate a high rate of return on my equity ownership in the company. You can see the past 10 years of ROE for Unilever Plc.

Tuesday, June 9, 2015

Top 10 Medical Stocks For 2015

Garry L./Shutterstock In America, we believe that everyone deserves a second chance. If you've seen your credit suffer due to bankruptcy, joblessness, medical bills or just a pattern of poor decisions, there is always a way for you to re-establish your credit. The problem is that you must obtain credit in order to build it, but it can be difficult to find a reputable lender when you have poor credit. A secured credit card can help. These cards require users to place a deposit with the bank as a condition of opening their account. The deposit is held as a security against default, but in all other ways secured cards are just like standard credit cards. Cardholders receive monthly bills that they must pay, and they will incur interest on any balance they carry over until the next month. The good news is that payments are reported to the major consumer credit reporting agencies, so that your credit score will rise with your record of timely payments. Also, some of these cards come with benefits such as rental car collision damage waiver coverage, and standard consumer protections under federal law. For example, the Fair Credit Billing Act ensures that credit card users do not have to pay for fraudulent charges or goods not received. Finally, nearly anyone can qualify for a secured card once they have discharged any bankruptcies and proven their identity. How We Chose the Winners While there are some excellent secured cards on the market, there are also some inferior products with excessively high rates and fees. We looked for cards with a low annual fee, low interest rates and an affordable minimum deposit. Other valuable benefits can include rental car coverage, a credit limit beyond the deposit amount, cellphone insurance and even a travel rewards program. These are all things applicants should consider when trying to find the best secured credit card. As you work to build credit with a secured credit card, it's also good to get into the habit of monitoring your credit. Free tools can help you do that, like at Credit.com, where you get two credit scores and an overview of your credit profile updated every month, along with a personalized plan to help you build your credit over time. Now, let's take a look at this month's Best Credit Cards in America picks for the best secured credit cards.

Top 10 Small Cap Companies For 2016: Bellicum Pharmaceuticals Inc (BLCM)

Bellicum Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company�� product pipeline includes clinical product candidates, such as BPX-501, which is an adjunct T-cell therapy administered after allogeneic hematopoietic stem cell transplantation; BPX-201, which is a dendritic cell cancer vaccine; and Preclinical product candidates, including BPX-701, which is a T cell receptor (TCR) product candidate for solid tumors; BPX-401, which is a CAR-T product candidate for hematological cancers that express the CD19 antigen, and BPX-601, which is a TCR product candidate for solid tumors expressing the preferentially-expressed antigen in melanoma (PRAME). The Company�� Chemical Induction of Dimerization (CID) technology platform engineers and controls components of the immune system in real time.

CaspaCIDe

CaspaCIDe is the Company�� Chemical Induction of Dimerization (CID) safety switch technology. The CaspaCIDe eliminates cells in the event of toxicity. The CaspaCIDe switch consists of the CID-binding domain coupled to the signaling domain of caspase-9 (iCasp9), an enzyme that is part of the apoptotic pathway. The infusion of rimiducid triggers activation of this domain of caspase-9, which in turn leads to selective apoptosis of the CaspaCIDe-containing cells. The CaspaCIDe technology is applied to its lead clinical product candidate, BPX-501 and to its TCR product candidate, BPX-701.

The CaspaCIDe technology has demonstrated clinical efficacy in human patients beginning as soon as 30 minutes after administration of the activating drug, rimiducid. In the preclinical studies, rimiducid reduced or eliminated CaspaCIDe-containing cells in a dosage dependent manner. The National Cancer Institute is conducting a Phase I/II clinical trial for sarcoma! and other solid tumors with a chimeric antigen receptor (CAR) construct targeting a solid tumor antigen combined with CaspaCIDe.

CIDeCAR

CIDeCAR Technology consists of a CAR T cell that incorporates its co-stimulatory domain, MC, for improved T-cell activation and proliferation, and the CaspaCIDe safety switch. CAR interaction with cancer cell antigens leads to MC signaling, which then leads to activation of T cells. In the event of serious toxicity, rimiducid activation of caspase-9 eliminates the CIDeCAR T cells.

The Company has conducted proof-of-principle preclinical studies for CIDeCAR technology, CIDeCAR candidate BPX-401 and CIDeCAR solid tumor CAR targeting Her2, in which, both were evaluated in vitro. These preclinical studies demonstrated that CIDeCAR technology results in enhanced activation, proliferation and tumor cell killing; and the elimination of these CIDeCAR T cells after exposure to rimiducid.

GoCAR-T

The Company�� GoCAR-T technology incorporates a switch that activates CAR T cells when triggered by both rimiducid and the targeted antigen expressed on the surface of the cancer cells. The GoCAR-T technology separates the CIDeCAR dual co-stimulatory domain, MC, from the antigen recognition domain and moves it onto a separate molecular switch that can be controlled by rimiducid. GoCAR-T cells can only be fully activated when exposed to both the cancer cells and rimiducid. This separation controls the degree of activation of the CAR T cells through adjustments to the amount of rimiducid administered, but still in a tumor-dependent manner.

The Company conducted a proof-of-principle in vitro study for GoCAR-T technology, in which it demonstrated that the GoCAR-T cells targeting the PSCA antigen can only be fully activated, as evidenced by production of IL-2 (left panel) and T-cell proliferation (right panel) when the GoCAR-T cells are exposed to both their target PSCA-expressing human pancreatic cancer cells ! and rimid! ucid. In further in vivo studies of GoCAR-T technology, target antigen PSCA-expressing Capan-1 human pancreatic tumors were established in immune-deficient, or NSG, mice. After seven days, five mice received control T cells modified only with firefly luciferase, an imaging protein, and 10 mice received T cells modified with MC in the form of a molecular switch or iMC, plus a PSCA. CAR (together, BPX-601) and firefly luciferase. Five mice in this second group also received 5 mg/kg rimiducid weekly. T-cell imaging clearly demonstrated that GoCAR-T cells can be stimulated to proliferate in vivo when exposed to target antigen-expressing cancer cells by rimiducid administration.

DeCIDe

The DeCIDe technology is used to control the activation of dendritic cells. The DeCIDe technology couples the signaling domains of CD40 and MyD88 to its CID binding domain, to create inducible MC switch, which is then insert into dendritic cells along with the PSMA antigen to take control of the activation of the dendritic cells and the resulting immune response to cancer. Upon exposure to rimiducid, DeCIDe-containing dendritic cells become highly activated. The DeCIDe technology activates dendritic cells with rimiducid after the patient has been vaccinated and the dendritic cells have migrated to the draining lymph nodes.

The cultured BPX-201 cells transduced with DeCIDe switch technology produce supra-normal levels of IL-12 in response to rimiducid. These data demonstrates that, in addition to the temporal control of dendritic cell activation that DeCIDe technology affords, once exposed to rimiducid, DeCIDe-containing dendritic cells become highly activated, which may lead to more potent anti-cancer activity in patients.

BPX-501

The Company�� CaspaCIDe product candidate BPX-501, is under development for the treatment of hematological diseases. BPX-501 is an adjunct T-cell therapy administered after allogeneic hematopoietic stem cell transplantation (HSCT), us! ing donor! stem cells. The BPX-501 eliminates donor T cells through the triggering of the CaspaCIDe safety switch upon emergence of Graft-versus-host disease (GvHD). The BPX-501 improves stem cell engraftment and accelerates immune system recovery, while providing for resolution of GvHD. The BPX-501 has a range of applications: an add-back of donor T cells administered to accelerate immune system recovery after allogeneic haplo-HSCT in which the T cells in the transplanted stem cells were depleted, and a donor T-cell infusion administered to prevent or treat relapse of underlying disease after allogeneic HSCT independent of donor match.

The product has undergone a 10-patient Phase I clinical trial with CaspaCIDe modified T cells. Four patients developed GvHD after donor T-cell infusion. A single dosage of rimiducid eliminated around 90% of the modified T cells and resolved GvHD in all four patients without recurrence of GvHD. In the second clinical trial of CaspaCIDe-modified T cells, these demonstrations have been replicated in preliminary data from three patients. BPX-501 is being evaluated in multiple Phase I/II clinical trials in the United States, which includes BP-001, a clinical trial in adults and and BP-003, a clinical trial in children. During the BP-001 clinical trial, BPX-501 is administered after initial allogeneic HSCT for hematological cancers. The BP-003 clinical trial in children with orphan inherited blood disorders includes the administration of BPX-501 after initial allogeneic HSCT. The Company also initiated an additional Phase I/II clinical trial, BPX-004 in children with hematological cancers or orphan inherited blood disorders.

BPX-201

The Company�� product candidate under development, BPX-201 is a dendritic cell cancer vaccine intended to treat metastatic castrate-resistant prostate cancer (mCRPC). BPX-201 is an autologous therapy, in which the patient�� own white blood cells are extracted and modified ex vivo. The cells are matured and then gen! etically ! engineered to express the DeCIDe switch domains and the prostate-specific membrane antigen (PSMA) antigen. The modified cells are then washed, apportioned into individual dosages, and frozen for later administration to the patient. The incorporation of the DeCIDe switch in the presence of rimiducid activates the therapy.

The Company is evaluating BPX-201 in an 18-patient Phase I clinical trial for mCRPC. It is evaluating opportunities for BPX-201 in combination with other cancer immunotherapies, such as checkpoint inhibitors.

BPX-701

The Company�� CaspaCIDe T cell receptor (TCR) Product Candidate, BPX-701 is under development for the treatment of Solid Tumors. BPX-701 is a TCR-based therapy for the treatment of PRAME-expressing melanoma, sarcomas and neuroblastomas. BPX-701 is designed to target preferentially-expressed antigen in melanoma (PRAMEa gene) that is predominantly expressed in human melanomas but not in normal tissues.

The BPX-701 has demonstrated complete elimination in response to rimiducid. The Clinical Cancer Research 2011 has demonstrated that PRAME-specific clones showed high reactivity against a panel of PRAME positive tumor cell lines, metastatic melanoma, sarcomas and neuroblastoma tissues, and no reactivity against normal cell types, with the exception of low reactivity against kidney epithelial cells and intermediate reactivity against mature dendritic cells. The vitro studies demonstrated BPX-701�� affinity to panels of cancer cells presenting PRAME peptides and low affinity to non-tumor cells. In other in vitro studies, rimiducid administration has proved the ability to eliminate BPX-701 cells.

BPX-401

The Company�� CIDeCAR Product Candidate under development, BPX-401, is developed for the treatment of Hematological Cancers, such as acute lymphotcytic leukemia (ALL), chronic lymphocytic leukemia (CLL), and certain types of non-Hodgkin�� lymphoma. The CIDeCAR consists of CAR T cells modified to! include ! its CaspaCIDe safety switch and in which the CAR incorporates the signaling domains of two proteins, MyD88 and CD40. These proteins form the Company�� dual co-stimulatory domain, MC, which is designed to activate T cells in the presence of cancer cells. The Company has generated preclinical proof-of-principle data in vitro signifying that BPX-401 has CAR T cell activation and proliferation potential, and may be effective in killing cancer cells.

BPX-601

The Company�� GoCAR-T Product Candidate, BPX-601, is proposed for the treatment of Solid Tumors. The BPX-601 is undergoing preclinical studies for the treatment of solid tumors overexpressing the prostate stem cell antigen (PSCA), such as some prostate, pancreatic, bladder, esophageal and gastric cancers. The Company�� GoCAR-T technology consists of CAR and T cells. GoCAR-T controls activation and proliferation of the CAR T cells through the scheduled administration of a course of rimiducid infusions.

BPX-601 is undergoing preclinical studies for the treatment of solid tumors overexpressing the PSCA antigen. The Company has demonstrated positive proof-of-principle data in an animal pancreatic tumor model.

The Company competes with Adaptimmune Limited, bluebird bio, Inc., Celgene Corporation, Cellectis SA, GlaxoSmithKline plc, Intrexon Corporation, Juno Therapeutics, Inc., Kite Pharma, Inc., Novartis AG and Pfizer Inc.

Advisors' Opinion:
  • [By John Udovich]

    Small cap cancer drug stock Kite Pharma Inc (NASDAQ: KITE) has surged after announcing a�strategic research collaboration and license agreement with Amgen, Inc (NASDAQ: AMGN)�involving Chimeric Antigen Receptors (CAR) ��meaning its worth taking a closer look at the stock, which had an IPO last June,�along with potential peers�Bellicum Pharmaceuticals Inc (NASDAQ: BLCM) and Juno Therapeutics (NASDAQ: JUNO) which are players in the CAR therapies space and had more recent IPOs.

Top 10 Medical Stocks For 2015: BIND Therapeutics Inc (BIND)

BIND Therapeutics, Inc., incorporated on May 19, 2006, is a clinical-stage nanomedicine platform company developing Accurins, its targeted and programmable therapeutics. Accurins are designed with specified physical and chemical characteristics to target specific cells or tissues and concentrate a therapeutic payload at the site of disease to enhance efficacy while minimizing adverse effects on healthy tissues. Its drug candidate, BIND-014, is in Phase II clinical trials for non-small cell lung cancer, or NSCLC, and metastatic castrate-resistant prostate cancer (mCRPC).

Accurins represent the evolution of targeted therapies and nanomedicine. Accurins are polymeric nanoparticles that incorporate a therapeutic payload and are designed to have prolonged circulation within the bloodstream, enable targeting of the diseased tissue or cells, and provide for the controlled and timely release of the therapeutic payload. The four components include Targeting ligands, Stealth and protective layer, Controlled-release polymer matrix and Therapeutic payload. The Company focuses to use its medicinal nanoengineering platform to develop Accurins in several therapeutic areas, with an initial focus on the treatment of various types of cancer. In addition, the Company entered into collaboration agreements with several biopharmaceutical companies to develop and commercialize Accurins that are based on its collaborators��therapeutic payloads. The Company�� programs include BIND-014, solid tumor accurin and hematologic cancer accurin.

Advisors' Opinion:
  • [By John Udovich]

    The biotech sector has been pretty exciting this year�with small cap biotech stocks Prana Biotechnology Limited (NASDAQ: PRAN) and TNI BioTech (OTCMKTS: TNIB) having recently produced noteworthy news for investors�while Acceleron Pharma, Inc (NASDAQ: XLRN), Ophthotech (NASDAQ: OPHT) and BIND Therapeutics (NASDAQ: BIND) have just�set term sheets for their upcoming IPOs. Just consider all of the following recent news:

  • [By Anna Prior]

    Bind Therapeutics sa(BIND)id a collaboration with Amgen Inc.(AMGN) has been ended after both companies agreed not to pursue an option to jointly develop a molecularly targeted cancer therapy. Bind Therapeutics shares fell 11% to $11.50 premarket.

Top 10 Medical Stocks For 2015: Juno Therapeutics Inc (JUNO)

Juno Therapeutics, Inc. (Juno) is a United States-based clinical-stage biopharmaceutical company. The Company is engaged in developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR), and high-affinity T cell receptor (TCR), technologies to genetically engineer T cells to recognize and kill cancer cells. Through genetic engineering, the Company inserts a gene for a particular CAR or TCR construct into the T cell that enables it to better recognize cancer cells. Its CAR technology directs T cells to recognize cancer cells based on the expression of specific proteins located on the cell surface, whereas its TCR technology provides the T cells with a specific T cell receptor to recognize protein fragments derived from either the surface or inside the cell.

To provide treatment, the Company harvests blood cells from a cancer patient, separate the appropriate T cells, activate the cells, insert the gene sequence for the CAR or TCR construct into the cells��Deoxyribonucleic Acid (DNA), and grow these modified T cells to the desired dose level. The modified T cells can then be infused into the patient or frozen and stored for later infusion. Once infused, the T cells are designed to multiply, through a process known as cell expansion, when they encounter the targeted proteins and to kill the targeted cancer cells.

CD19-Directed Product Candidates

The Company�� product candidates, such as JCAR015, JCAR017, and JCAR014, which use CAR technology to target CD19, a protein expressed on the surface of almost all B cell leukemias and lymphomas. The Company has rights to commercialize each of these product candidates across the world. The Company�� JCAR015 is an advanced development product candidate, and it has demonstrated clinically meaningful complete remission rates in adult patients with r/r ALL. JCAR015 uses the CD28 costimulatory domain and CD3 enriched peripheral blood mononuclear cells (PBMC), which requires fewer process steps for! manufacture than its defined cell composition product candidates. JCAR015 is being tested in a Phase I open label clinical trial of patients with r/r ALL for the treatment of refractory chronic lymphocytic leukemia.

JCAR017 also targets CD19, but differs from JCAR015 in several important respects. JCAR017 uses the 4-1BB costimulatory domain and a defined cell composition of CD4+ T cells and CD8+ T cells. JCAR017 is in development for pediatric patients with r/r ALL. JCAR017 is being evaluated in a Phase I/II clinical trial in pediatric r/r ALL.

JCAR014 also targets CD19. JCAR014 uses the 4-1BB costimulatory domain and is composed of CD8+ central memory T cells and CD4+ T cells in a defined ratio. JCAR014 is being evaluated in a Phase I/II trial as a treatment for a number of B cell malignancies in patients relapsed or refractory to standard therapies.

Additional Product Candidates

The Company is exploring the potential of its CAR and TCR technologies against targets that have the potential to treat cancers not targeted by CD19-directed products, in particular, difficult-to-treat solid organ tumors, such as certain breast, lung, and pancreatic cancers, as well as B cell malignancies that do not express CD19. The Company�� CD22 is a cell surface protein widely expressed on B lymphocytes. It is expressed by B cell malignancies, including non-Hodgkin�� lymphoma (NHL), acute lymphoblastic leukemia (ALL), and chronic lymphocytic leukemia (CLL). The Company�� L1CAM, also known as CD171, is a cell-surface adhesion molecule that plays an important role in the development of a normal nervous system. It is overexpressed in neuroblastoma, and there is increasing evidence of aberrant expression in a variety of solid organ tumors, including glioblastoma and lung, pancreatic, and ovarian cancers.

The Company�� MUC-16 is a protein overexpressed in the ovarian cancers, but not on the surface of normal ovary cells. CA-125 is a protein found in the ! blood of ! ovarian cancer patients that results from the cleavage of MUC-16. CA-125 levels in the blood are a common test for ovarian cancer progression because they correlate with cancer progression. Its MUC-16/IL-12 product candidate uses its armored CAR technology. IL-12 is a cytokine that can help overcome the inhibitory effects that the tumor micro-environment can have on T cell activity.

The Company�� ROR-1 is a protein expressed in the formation of embryos, but in normal adult cells its surface expression is predominantly found at low levels on adipocytes, or fat cells, and briefly on precursors to B cells, or pre-B cells, during normal B cell maturation. ROR-1 is overexpressed on a variety of cancers including a subset of non-small cell lung cancer, triple negative breast cancer, pancreatic cancer, and prostate cancer. It is expressed on B cell chronic lymphocytic leukemia and mantle cell lymphoma. The Company�� high-affinity TCR T cell product candidate targets WT-1, an intracellular protein that is overexpressed in a number of cancers, including adult myeloid leukemia, or AML, and non-small cell lung, breast, pancreatic, ovarian, and colorectal cancers.

Advisors' Opinion:
  • [By John Udovich]

    Small cap cancer drug stock Kite Pharma Inc (NASDAQ: KITE) has surged after announcing a�strategic research collaboration and license agreement with Amgen, Inc (NASDAQ: AMGN)�involving Chimeric Antigen Receptors (CAR) ��meaning its worth taking a closer look at the stock, which had an IPO last June,�along with potential peers�Bellicum Pharmaceuticals Inc (NASDAQ: BLCM) and Juno Therapeutics (NASDAQ: JUNO) which are players in the CAR therapies space and had more recent IPOs.

Top 10 Medical Stocks For 2015: Rexahn Pharmaceuticals Inc (RNN)

Rexahn Pharmaceuticals, Inc. (Rexahn) is a development-stage biopharmaceutical company. The Company focuses on the development of cures for cancer to patients worldwide. The Company�� pipeline features one drug candidate in Phase II clinical trials. The Company also has several other drug candidates in pre-clinical development. In addition, the Company has two renal cell carcinoma (CNS) candidates, Serdaxin, CNS Disorders drug for depression and neurodegenerative diseases and Zoraxel, which is a erectile dysfunction (ED) and sexual dysfunction drug that are in clinical stages and the Company is are exploring options for further development . The Company�� drug candidate, Archexin is an anticancer Akt inhibitor.

Archexin

Archexin is potent inhibitor of the Akt protein kinase (Akt) in cancer cells. Archexin has FDA orphan drug designations for five cancers (RCC, glioblastoma, and cancers of the ovary, stomach and pancreas). Multiple indications for other solid tumors can also be pursued. Archexin inhibit both activated and inactivated forms of Akt, and to reverse the drug resistance observed with the protein kinase inhibitors. Archexin is an antisense oligonucleotide (ASO) compound that is complementary to Akt mRNA, and selective for inhibiting mRNA expression and production of Akt protein. As of December 31, 2011, Archexin was in Phase II clinical trials for the treatment of pancreatic cancer with enrollment completed in September, 2011.

Serdaxin

Serdaxin is an extended release formulation of clavulanic acid, which is an ingredient present in antibiotics approved by the FDA. The Company had been developing Serdaxin for the treatment of depression and neurodegenerative disorders. From January to September, 2011, the Company conducted a randomized, double-blind, placebo-controlled study compared two doses of Serdaxin, 0.5 milligram and 5 milligram, to placebo over an eight-week treatment period for major depressive disorder (MDD) patients. As of Dec! ember 31, 2011, the Company had not made a determination of Serdaxin�� future paths or resource allocations to further develop Serdaxin to treat MDD.

Zoraxel

Zoraxel is an orally administered, on-demand tablet to treat sexual dysfunction. Zoraxel is a dual enhancer of neurotransmitters in the brain that play a key role in sexual activity phases of motivation and arousal, erection and release, and may be the ED drug to affect all three of these phases of sexual activity. As of December 31, 2011, the Company was evaluating how to proceed with the Phase IIb study of Zoraxel.

The Company�� Pre-clinical Pipeline Drug Candidates includes RX-1792, which is a small molecule anticancer EGFR inhibitor; RX-5902, which is a small molecule anticancer ribonucleic acid (RNA) helicase regulator; RX-3117, which is a Small molecule anticancer deoxyribonucleic acid (DNA) synthesis Inhibitor; RX-8243, which is a small molecule anticancer aurora kinase inhibitor; RX-0201-Nano, which is a nanoliposomal anticancer Akt inhibitor; RX-0047-Nano, which is an nanoliposomal anticancer HIF-1 alpha inhibitor and RX-21101, which is a nano-polymer Anticancer.

Advisors' Opinion:
  • [By James E. Brumley]

    At first glance, Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) doesn't look like anything particularly trade-worthy. The stock's now where it was in late October, and where it was in late September, and even where it was in late June. In other words, though RNN has been much higher and much lower than its current price of $0.46 over the course of the past several months, it doesn't look like it's going anywhere - on a net basis - anytime.

  • [By John Udovich]

    So far this year, Rexahn Pharmaceuticals, Inc (NYSEMKT: RNN), Imprimis Pharmaceuticals Inc (NASDAQ: IMMY) and Arrowhead Research Corp (NASDAQ: ARWR) are up 186.3%, 157.2% and 142.5%, respectively, since the start of the year���making them the best performing small cap biotech stocks for 2014. But given their lackluster performance over the past few years, what is the secret behind their phenomenal 2014 rise and will they keep rising? For starters, none of these small caps have really produced anything in the way of blockbuster news:

  • [By James E. Brumley]

    With just a quick glance at a chart of Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN), it would be easy to conclude it's nothing but a volatile mess. When you take a step back and look at a long-term weekly chart of RNN, however, it starts to become clear that this small cap biopharma name is on the verge of a monster-sized breakout. First things first, however.

  • [By James E. Brumley]

    If you were lucky enough to step into Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) when your truly suggested it was a budding buy back on December 23rd, then congratulations - you're now up a little more than 60% (assuming you bought into RNN after the break above a key resistance line on the 27th). Now get out. Instead, use your profits from the Rexahn to take on a stake in GTx, Inc. (NASDAQ:GTXI). No, GTXI may not look like much at first, but when you take a step back and look at a chart of GTx, Inc. through a longer-term lens, the upside potential becomes clear.

Top 10 Medical Stocks For 2015: ResMed Inc (RMD)

ResMed Inc., (ResMed), incorporated on March 31, 1994, is a holding company for the ResMed Group. The Company, through its subsidiaries, is a developer, manufacturer and distributor of medical equipment for treating, diagnosing, and managing sleep-disordered breathing and other respiratory disorders. Sleep-disordered breathing (SDB) includes obstructive sleep apnea (OSA), and other respiratory disorders that occur during sleep. The Company has developed a number of products for SDB and other respiratory disorders including airflow generators, diagnostic products, mask systems, headgear and other accessories. Its manufacturing operations are located in Australia, Singapore, France, Germany, Malaysia and the United States. Its distribution and sales sites are located in the United States, Germany, France, the United Kingdom, Switzerland, Australia, Japan, Norway and Sweden. In December 2013, ResMed Inc acquired Unimedis SRO, a surgical appliance and manufacturing company.

Air Flow Generators

The Company produces continuous positive airway pressure (CPAP), variable positive airway pressure (VPAP) and AutoSet systems for the titration and treatment of SDB. The flow generator systems deliver positive airway pressure through a patient interface, either a small nasal mask, nasal pillows system, or full-face mask. Its VPAP units deliver bilevel therapy. There are two preset pressures: a higher pressure as the patient breathes in, and a lower pressure as the patient breathes out. AutoSet systems are based on a technology to monitor breathing and can also be used in the diagnosis, treatment and management of OSA. The Company�� Stellar 100 and 150 ventilation devices, provide both invasive and non invasive ventilation applications for adult and pediatric patients.

ResMed Inc.�� CPAP products include S8 Escape, S9 Elite and S9 Escape. Its VPAP products include VPAP III STA with QuickNav, VPAP S / VPAP IV, VPAP IV ST, S8 Auto 25, VPAP Tx Lab System, S9 VPAP S, S9 VPAP ST! , S9 VPAP Auto, S9 VPAP Adapt, S9 AutoSet CS, S9 Auto 25 and S9 VPAP COPD. The Company�� automatic positive airway pressure products include S9 AutoSet and S9 Escape Auto. Its ventilation products include Elisee 150, VS III and Stellar 100 and 150.

Masks, Accessories, Motors and Diagnostic Products

Masks, accessories, motors and diagnostic products together accounted for approximately 46% of its net revenues in fiscal 2012. Its Mask products include Activa LT, Swift LT for Her, Swift FX, Mirage SoftGel, Quattro FX, Swift FX for Her, Mirage FX, Mirage FX for Her, Pixi Pediatric Mask, Quattro FX for Her, Swift FX Bella, Quattro Air and Swift FX Nano. Its diagnostic products includes ApneaLink + Oximetry and ApneaLink Plus (U.S.)

Accessories and Other Products

The Company to assist those professionals diagnosing or managing the treatment of patients have data communications and control products, such as the EasyCare, ResLink, ResControl, ResControl II, TxControl, ResScan and ResTraxx modules that facilitate the transfer of data and other information to and from the flow generators. These products include humidifiers, such as H5i and H4i, which connect directly with the CPAP, VPAP and AutoSet flow generators to humidify and heat the air delivered to the patient, helping to prevent the drying of nasal passages that can cause discomfort. Other optional accessories include cold passover humidifiers, carry bags and breathing circuits. The Company�� data/patient management products include S9 Embletta Adapter, ResScan v3.14, ResTraxx v17.1., ResTraxx v18.3, ResScan v3.16 and EasyCare 1.0.

The Company competes with Philips BV, DeVilbiss Healthcare., Fisher & Paykel Healthcare Corporation Limited, Apex Medical Corp, BMC Medical Co. Ltd and Weinmann Gerate fur Medizin GmbH + Co. KG.

Advisors' Opinion:
  • [By Sean Williams]

    ResMed (NYSE: RMD  ) : 2% projected forward yield
    Like the previous companies, ResMed has operations on a global scale, but unlike the preceding device makers, its focus is on medical equipment that helps diagnose and treat sleeping disorders. Whereas growth at Smith & Nephew and Medtronic has been slow-and-go in recent quarters, ResMed has seen sales take off. In its recently reported fourth-quarter results, ResMed delivered record quarterly revenue and income of $414.6 million and $86.2 million. Revenue in its Americas and combined Europe/Asia Pacific regions rose by 11% and 12%, respectively, with the company announcing a 47% increase to its quarterly dividend.�

Top 10 Medical Stocks For 2015: Synageva BioPharma Corp (GEVA)

Synageva BioPharma Corp., incorporated in 1993, is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutic products. It has several protein therapeutics in development, including two enzyme replacement therapies for lysosomal storage disorders and two programs for life-threatening genetic conditions. Its lead program, SBC-102, recombinant human lysosomal acid lipase (LAL), is its advanced pipeline program in clinical development for LAL Deficiency. This enzyme is responsible for the metabolism of cholesteryl esters and triglycerides that are delivered to lysosomes by a variety of routes, including low-density lipoprotein receptor mediated endocytosis. On November 2, 2012, Trimeris, Inc. merged with Synageva BioPharma Corp.

SBC-102 is produced by recombinant deoxyribonucleic acid (DNA) technology in egg white using its protein manufacturing platform. The Company has initiated natural history studies in approximately 20 countries. In addition to SBC-102, it is progressing protein therapeutic programs for other rare diseases, which are at different stages of preclinical development. These include two enzyme replacement therapies for other lysosomal storage disorders and two programs for other rare life-threatening conditions. As of December 31, 2011, its product candidate pipeline included SBC-102, SBC-103, SBC-104, SBC-105 and SBC-106.

SBC-104 is an extracellular protein that targets a severe, rare genetic condition. SBC-105 is an enzyme replacement therapy being developed to treat a severe, rare metabolic disorder. SBC-106 is a protein therapy that targets a severe and rare genetic condition.

Advisors' Opinion:
  • [By Ben Levisohn]

    Somaiya and team named Gilead and�Neurocrine Biosciences (NBIX) their top picks, hile putting Buy ratings on Celgene, Biogen Idec, Alexion (ALXN), Incyte (INCY), Pharmacyclics (PCYC) and Synageva (GEVA). BioMarin (BMRN), Infinity Pharmaceuticals (INFI) and Amgen (AMGN) earned Neutral ratings.

  • [By Garrett Cook]

    Shares of Synageva BioPharma (NASDAQ: GEVA) were down 14.42 percent to $89.69 after the company reported that Phase 3 study met primary endpoint and six secondary endpoints across multiple disease-related abnormalities. Citigroup initiated coverage on Synageva BioPharma with a Neutral rating.

Top 10 Medical Stocks For 2015: Hemispherx Biopharma Inc (HEB)

Hemispherx Biopharma, Inc. (Hemispherx) is a specialty pharmaceutical company engaged in the clinical development of new drugs therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders. Hemispherx focuses on two core pharmaceutical technology platforms Ampligen and Alferon N Injection.The commercial focus for Ampligen includes application as a treatment for Chronic Fatigue Syndrome (CFS) and as an influenza vaccine enhancer (adjuvant) for both therapeutic and preventative vaccine development. Alferon N Injection is a United States Food and Drug Administration (FDA) approved product with an indication for refractory or recurring genital warts. Alferon LDO (Low Dose Oral) is a formulation under development targeting influenza. It has three subsidiaries BioPro Corp., BioAegean Corp., and Core BioTech Corp. The Company's foreign subsidiary is Hemispherx Biopharma Europe N.V./S.A.

Ampligen

Ampligen is an experimental drug, which is undergoing clinical development for the treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). Over 1,000 patients have participated in the Ampligen clinical trials representing the administration of more than 90,000 doses of this drug. The Company is also engaged in ongoing, experimental studies assessing the efficacy of Ampligen against influenza viruses.

Alferon N Injection

Alferon N Injection is the registered trademark for the Company's injectable formulation of natural alpha interferon. Interferons are a group of proteins produced and secreted by cells to combat diseases. The Company's natural alpha interferon is produced from human white blood cells. Alferon N Injection [Interferon alfa-n3 (human leukocyte derived)] is a highly purified, natural-source, glycosylated, multi-species alpha interferon product.

Alferon LDO (Low Dose Oral)

Alferon LDO [Low Dose Oral Interferon Alfa-n3 (Human Leukocyte Derived)]! is an experimental low-dose, oral liquid formulation of Natural Alpha Interferon and like Alferon N Injection should not cause antibody formation, which is a problem with recombinant interferon. It is an experimental immunotherapeutic that works by stimulating an immune cascade response in the cells of the mouth and throat, enabling it to bolster systemic immune response through the entire body by absorption through the oral mucosa.

The Company competes with Pfizer, GlaxoSmithKline, Merck, AstraZeneca, Baxter International, Fletcher/CSI, AVANT Immunotherapeutics, AVI BioPharma and Genta.

Advisors' Opinion:
  • [By Matt Egan]

    Shares of Hemispherx Biopharma (HEB) soared 11% on Wednesday amid the rising Ebola fears. Earlier this week, the company announced a series of research collaborations aimed at developing treatments to fight Ebola.